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Abstract 
The term glycation is used to describe the sequence of non-
enzymatic reactions, in which biomolecules with nucleophilic groups 
including proteins, lipids and nucleic acids react with sugars, resulting 
finally in the formation of complex Advanced Glycation End Products 
(AGEs). Long-lived proteins are particularly vulnerable and undergo 
remarkable structural and conformational alterations including aggregation 
and fragmentation. Glycation is also accompanied by the formation of 
reactive oxygen species (ROS) that may exacerbate the damage to the 
protein undergoing glycation and also those in its viscinity. The damage 
caused to a large number of proteins and enzymes by in vitro and in vivo 
glycation by various sugars has been extensively investigated. 
Impaired resistance to infection has long been associated with 
uncontrolled diabetes. While the exact mechanism of the enhanced 
susceptibility of diabetics to various infections is incompletely understood, 
potential target candidates include immunoglobulins that contribute towards 
humoral and cell-mediated immunity. Various immunoglobulins have been 
shown to undergo glycation reaction with sugars, both in vitro and in vivo. 
It was therefore considered of interest to investigate if immunoglobulins 
derived from some mammalian and an avian source differs in their 
susceptibility to glycation. 
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Immunoglobulin G was purified to homogeneity from goat, human, 
rabbit, mouse and buffalo sera as well as from hen egg yolk, using ion-
exchange chromatography on DEAE-cellulose. These purified IgG were 
then subjected to in vitro glycation with fructose. The behaviour of glycated 
IgG was investigated by SDS-PAGE and determining hyperchromicity at 
280 nm, tryptophan fluorescence, new fluorescence and by colorimetric 
analysis. Marked differences were observed in the response of the 
immunoglobulins derived from various animals to incubation with fructose. 
SDS-PAGE revealed a decrease in the intensity of the immunoglobulin 
bands. The decrease appeared most prominent in case of hen egg yolk IgY 
followed by IgG derived from buffalo, mouse, rabbit, human and goat sera. 
Comparable changes were evident when increase new fluorescence, 
increase in carbonyl content and decrease in amino group content of the 
immunoglobulins incubated with fructose were determined. 
Hyperchromicity and tryptophan quenching was observed in all cases but 
the order of alterations was not identical with that observed in case of new 
fluorescence. Overall, the goat IgG were most recalcitrant while hen egg 
yolk IgY were most susceptibile to the investigated alterations. DETAPAC 
or EDTA restricted but did not prevent the fructose-induced alterations. 
Incubation of anti-glucose oxidase-IgG with fructose also resulted in a rapid 
loss of their ability to bind the enzyme antigen as revealed by 
immunodiffusion and ELISA. 
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Using Aspergillus niger glucose oxidase as a model, protective effect 
of anti-enzyme-antibodies against alteration in enzyme activity was 
investigated. There was a progressive decrease in the glucose oxidase 
activity on incubation with sugars and after 8 days of incubation with 
glucose, fructose or ribose the loss in enzyme activity was 71, 88 and 96 
percent respectively. The enzyme inactivation was accompanied by 
decrease in intensity of the glucose oxidase band that also migrated in a 
diffused form on SDS-PAGE. Also, glucose oxidase incubated with sugar 
was quite rich in carbonyl groups as compared to the enzyme not exposed 
to the sugars. Antibodies purified from the sera of glucose oxidase 
immunized rabbits and the F(ab)"2 or F(ab)" derived thereof were 
remarkably effective in restricting the inactivation of the enzyme induced 
by the sugars, providing up to 90 percent protection against loss of catalytic 
activity. Both the intact antibodies and the fragments exhibited glycation-
induced alterations in electrophoretic behaviour, which were however 
minimized when they were incubated along with glucose oxidase. The 
sugar-induced alterations were most prominent with ribose followed by 
fructose and glucose. These studies suggest the potential of immunotherapy 
with anti-enzyme-antibodies in the restriction of complications associated 
with in vivo glycation reactions. 
Antibodies were been raised against groups generated on incubation 
of proteins with fructose by immunizing rabbits with fructated-BSA. The 
affinity-purified antibody specifically human IgG incubated with fructose 
but not with other reducing sugars such as glucose, galactose or ribose as 
judged by ELISA and immunoblotting. Similarly, on western blotting an 
intense stain was visible in lane which contained human IgG exposed to 
fructose while no bands appeared in lanes containing the immunoglobulin 
not exposed to the sugars as well as those containing human IgG treated 
with glucose, galactose or ribose. Also, the level of fructation in 
immunoglobulins from various mammalian sources and an avian source 
undergone on in vitro incubation with fructose was appreciably detected 
and differentiated by the anti-(fructosyl group)-antibody on ELISA. The 
specificity of the antibody was further elucidated by a set of experiments 
involving interrupted glycation. Human IgG subjected to uninterrupted and 
interrupted treatment with fructose when tested on ELISA by the anti-
(fructosyl group)-antibody showed no significant increase in 
immunoreactivity towards the sample subjected to interrupted incubation 
although fluorescence and behavior in SDS-PAGE indicated marked 
increase the glycation in the latter. These observations suggests that 
interrupted glycation may lead to the formation of groups/AGEs that are not 
recognized by the antibody. 
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Abstract 
The term glycation is used to describe the sequence of non-enzymatic 
reactions, in which biomolecules with nucleophilic groups including proteins, 
lipids and nucleic acids react with sugars, resulting finally in the formation of 
complex Advanced Glycation End Products (AGEs). Long-lived proteins are 
particularly vulnerable and undergo remarkable structural and conformational 
alterations including aggregation and fragmentation. Glycation is also 
accompanied by the formation of reactive oxygen species (ROS) that may 
exacerbate the damage to the protein undergoing glycation and also those in its 
viscinity. The damage caused to a large number of proteins and enzymes by in 
vitro and in vivo glycation by various sugars has been extensively investigated. 
Impaired resistance to infection has long been associated with 
uncontrolled diabetes. While the exact mechanism of the enhanced susceptibility 
of diabetics to various infections is incompletely understood, potential target 
candidates include immunoglobulins that contribute towards humoral and cell-
mediated immunity. Various immunoglobulins have been shown to undergo 
glycation reaction with sugars, both in vitro and in vivo. It was therefore 
considered of interest to investigate if immunoglobulins derived from some 
mammalian and an avian source differs in their susceptibility to glycation. 
Immunoglobulin G was purified to homogeneity from goat, human, rabbit, 
mouse and buffalo sera as well as from hen egg yolk, using ion-exchange 
chromatography on DEAE-cellulose. These purified IgG were then subjected to in 
vitro glycation with fructose. The behaviour of glycated IgG was investigated by 
SDS-PAGE and determining hyperchromicity at 280 nm, tryptophan fluorescence, 
new fluorescence and by colorimetric analysis. Marked differences were observed 
in the response of the immunoglobulins derived from various animals to 
incubation with fructose. SDS-PAGE revealed a decrease in the intensity of the 
immunoglobulin bands. The decrease appeared most prominent in case of hen egg 
yolk IgY followed by IgG derived from buffalo, mouse, rabbit, human and goat 
sera. Comparable changes were evident when increase new fluorescence, increase 
in carbonyl content and decrease in amino group content of the immunoglobulins 
incubated with fructose were determined. Hyperchromicity and tryptophan 
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quenching was observed in all cases but the order of alterations was not identical 
with that observed in case of new fluorescence. Overall, the goat IgG were most 
recalcitrant while hen egg yolk IgY were most susceptibile to the investigated 
alterations. DETAPAC or EDTA restricted but did not prevent the fructose-
induced alterations. Incubation of anti-glucose oxidase-IgG with fructose also 
resulted in a rapid loss of their ability to bind the enzyme antigen as revealed by 
immunodiffusion and ELISA. 
Using Aspergillus niger glucose oxidase as a model, protective effect of 
anti-enzyme-antibodies against alteration in enzyme activity was investigated. 
There was a progressive decrease in the glucose oxidase activity on incubation 
with sugars and after 8 days of incubation with glucose, fructose or ribose the loss 
in enzyme activity was 71, 88 and 96 percent respectively. The enzyme 
inactivation was accompanied by decrease in intensity of the glucose oxidase band 
that also migrated in a diffused form on SDS-PAGE. Also, glucose oxidase 
incubated with sugar was quite rich in carbonyl groups as compared to the enzyme 
not exposed to the sugars. Antibodies purified from the sera of glucose oxidase 
immunized rabbits and the F(ab)'2 or F(ab)' derived thereof were remarkably 
effective in restricting the inactivation of the enzyme induced by the sugars, 
providing up to 90 percent protection against loss of catalytic activity. Both the 
intact antibodies and the fragments exhibited glycation-induced alterations in 
electrophoretic behaviour, which were however minimized when they were 
incubated along with glucose oxidase. The sugar-induced alterations were most 
prominent with ribose followed by fructose and glucose. These studies suggest the 
potential of immunotherapy with anti-enzyme-antibodies in the restriction of 
complications associated with in vivo glycation reactions. 
Antibodies were been raised against groups generated on incubation of 
proteins with fructose by immunizing rabbits with fructai:ed-BSA. The affinity-
purified antibody specifically human IgG incubated with fructose but not with 
other reducing sugars such as glucose, galactose or ribose as judged by ELISA 
and iinmunoblotting. Similarly, on western blotting an intense stain was visible in 
lane which contained human IgG exposed to fructose while no bands appeared in 
lanes containing the immunoglobulin not exposed to the sugars as well as those 
ii 
containing human IgG treated with glucose, galactose or ribose. Also, the level of 
fructation in immunoglobulins from various mammalian sources and an avian 
source undergone on in vitro incubation with fructose was appreciably detected 
and differentiated by the anti-(fructosyl group)-antibody on ELISA. The 
specificity of the antibody was further elucidated by a set of experiments 
involving interrupted glycation. Human IgG subjected to uninterrupted and 
interrupted treatment with fructose when tested on ELISA by the anti-(fructosyl 
group)-antibody showed no significant increase in immunoreactivity towards the 
sample subjected to interrupted incubation although fluorescence and behavior in 
SDS-PAGE indicated marked increase the glycation in the latter. These 
observations suggests that interrupted glycation may lead to the formation of 
groups/AGEs that are not recognized by the antibody. 
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1.0 Introduction 
1.1. Non-enzymatic glycosylation of biomolecules 
1.1.1. History 
In the beginning of the 20n century, Ling and Malting (1908) suggested for 
the first time that the color changes observed during browning of food were the 
result of reaction between sugars and proteins. This hypothesis was 
experimentally tested a few years later by Maillard (1912), who incubated various 
amino acids with glucose or other sugars and noticed that color of the solution 
changes to yellow and dark brown, accompanied by emission of carbon dioxide. 
The rates of reaction of various amino acids with sugars varied and Maillard, in 
addition to drawing up a relative scale of reactivity, hypothesized the role of such 
processes in biological environments. Only many decades later was the physio-
pathological relevance of these processes recognized: that they originate from the 
reaction of glucose or other reducing sugars, with nucleophilic groups of proteins 
and other molecules. The yield of products of such reactions is closely related to 
glucose concentration and they play an important role in pathology of diabetes 
(Trivelli et al, 1971). 
Maillard reaction, the first among the series of steps of glycation or non-
enzymatic glycosylation, involves the reaction of a reducing sugar with the s-
amino groups of lysine residues or the a-amino group of that at the N-terminus of 
proteins, resulting in the formation of a Schiff base. The Schiff base in turn 
undergoes a variety of complex transformations to yield Amadori products and 
finally to Advanced Glycosylation End Products (AGEs) (Gillery, 2001). AGE 
formation is also accompanied by the formation of a variety of reactive oxygen 
species (ROS) [Figure 1]. It is now well recognized that ROS generated thus also 
play an important role in tissue damage as well as in ageing and development of 
variety disorders including uremia (Hunt et al, 1988; Miyata et al, 1999) 
Alzheimer's disease (Dukic-Stefanovi et al, 2000), neuropathy (Sugimoto et al, 
2008) and several other disorders (Thornalley et al, 1999). 
The AGEs have been shown to accumulate in the circulation as well as in 
various tissues with age (Monnier et al, 1984), in atherosclerosis (Li et al, 1996; 
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Su et al, 2008), arthritis (Thomalley et al, 1999), osteoarthritis (DeGroot et al, 
2004), retinopathy (Yamagishi et al, 2006) and cancer (Stopper et al, 2003). The 
relationship between glycation and cardiovascular disease (CVD) seems 
remarkable and agents that restrict glycation have been shown to be 
cardioprotective indicating that AGEs may emerge as the new risk factors for the 
disease (Peppa et al, 2002). 
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Figure 1: Schematic representation of the non-enzymatic 
reaction of reducing sugars with protein 
(Lapolla et al., 2001). 
1.1.2. Chemistry of glycation 
Glycation involves a complex series of both parallel and sequential 
reactions between reducing sugars and nucleophilic groups of proteins and other 
molecules, giving rise to fluorescent and/or colored adducts (Cerami and Ulrich, 
2001). Proteins with high turnover and short lives do not accumulate AGEs, as 
they are rapidly degraded and eliminated, while long-lived proteins however tend 
to accumulate glycation adducts with age (Sell et al, 1996). The glycation adducts 
of intracellular protein are removed by their degradation with the help of 
lysosomal and other hydrolases present within the cell, whereas removal of 
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extracellular protein adducts requires specific recognition by the receptors, 
internalization and/or proteolytic processing (Horiuchi et al, 1996; Gugliucci et 
al, 1996). 
The process of glycation can be subdivided into three main stages: early, 
intermediate and late. In the early stage, glucose or other reducing sugars react 
reversibly with nucleophilic groups like amino groups of proteins, nucleic acids 
and lipids to form an unstable aldimine compound (Schiff base). Through 
rearrangement, the Schiff base undergoes transformation to the stable ketoamine 
(Amadori product). In vivo the non-enzymatic reactions depend on the 
concentration of sugar, reactivity of the free amino groups of biomolecules and 
their half-lives. The Amadori products may reach equilibrium after approximately 
15-20 days and accumulate both on short-lived and long-lived proteins 
(Thornalley, 1996). 
In the intermediate stage, the Amadori product is degraded into a variety 
of carbonyl compounds, such as glyoxal, methylglyoxal and deoxyglucosones that 
in turn act as propagators of the glycation reactions (Glomb and Monnier, 1995; 
Thornalley et al, 1999; Thornalley et al, 2003). The highly reactive ketoaldehyde 
molecules further react in the late stages, with other free amino groups through 
irreversible oxidation, dehydration and cyclization and form yellow-brown, 
heterogeneous compounds called AGEs [Figure 2]. Some AGEs possess 
functional groups that further react with amino and other side groups to cross-link 
proteins and form insoluble aggregates, with potential to disturb several 
pathophysiological functions (Thornalley, 1996). 
While the Amadori product formation leads to alterations in fluorescence, 
hyperchromicity, fragmentation, etc., autooxidative glycosylation may also 
contribute significantly to the above observed effects (Wolff and Dean, 1988). 
During the transition metal ion catalyzed autooxidation of sugars, alpha 
ketoaldehydes are formed which attack proteins and other biomolecules. Hydroxl 
radicals generated during autooxidation seem to be the key players in the 
conformational alterations and fragmentation that accompany incubation of 
proteins with sugars (Hunt et al, 1988). However, at least some of the reactions 
that follow Amadori product formation also generate hydroxyl radicals and others 
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PvOS (Ahmed et ah, 1986; Gillery, 2006), the relative contribution of the 
autooxidation and glycation to the protein damage becomes difficult to ascertain. 
Differentiation between reactions mediated via Amadori products and 
autooxidation of sugars has also been difficult in view of the similarity between 
the generated chromophoric and fluorophoric groups (Wolff et ah, 1984). 
Nonetheless, available evidences suggest the process of autooxidation or 
ketoaldehydes derived from there may contribute substantially to the sugar 
mediated alteration in proteins in vivo (Wolff and Dean, 1988). 
Amadori Products 
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Figure 2: Schematic representation of glycation of proteins and 
AGE formation. 
In vivo the AGEs may accumulate in the plasma, various tissues and on 
arterial wall as well as in the kidney mesangium, glomerular and basement 
membranes. Accumulation of AGEs in long-lived proteins appears to contribute to 
the age related increase in brown colour, fluorescence, poor solubility of oc-
crystallins and to a gradual decrease in the elasticity of connective tissue collagens 
[Figure 3]. These processes are enhanced in diabetics (Sell et ah, 1996). In fact the 
formation of AGEs may increase at greater rate than the increase in blood glucose 
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levels, suggesting that even moderate elevations in diabetic blood glucose levels 
can lead to substantial accumulation of the AGE (Ahmed, 2005). 
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Figure 3: Glycation-induced inactivation and crosslinking of 
protein (Kikuchi ei ah, 2002). 
A number of AGEs are formed in vitro under conditions simulating the 
physiological state and some of these have also been isolated from human 
tissues affected by disorders like diabetes. These include hydroimidazolones 
derived from deoxyglucosone, Nccarboxymethyl lysine, Ne-(l-carboxyethyl)-
lysine, pyrraline, several bis (lysyl) imidazolium derivatives, pentosidine, 
argpyrimidine and arginine derived Ns-(4-carboxy-4,6-dimethyl-
5,6dihydroxy-l,4,5,6-tetrahydropyrimidine-2-yl)-ornithine (Ahmed et ah, 
2002; Unoki and Yamagishi, 2008) [Figure 4]. In spite of the large number of 
efforts made, the exact chemistry of AGE formation is incompletely understood. 
Apparently the AGEs are highly heterogeneous, complex and clearly not all of 
these have been isolated (Singh et al, 2001; Ulrich and Cerami, 2001; Stitt, 2003; 
Gasser and Forbes, 2008). 
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1.1.3. Glycation with dicarbonyls 
Plasma from diabetic patients contains elevated levels of diarbonyl 
intermediates derived from sugars such as methyl glyoxal (MG), glyoxal and 3-
deoxyglucosone. These dicarbonyl compounds are more reactive than the parent 
sugars with respect to their ability to react with amino groups of protein and 
induce cross-links and AGE formation (Cho et al, 2007). MG may also arise in 
vivo from triose phosphate glycolytic intermediates (dihydroacetone phosphate 
and glyceraldehyde-3-phosphate), either by spontaneous elimination of the 
phosphate group or by decomposition of an ene-diol triose phosphate intermediate 
that leak from the active site of triose phosphate isomerase (Thornalley, 1999). 
The a-oxoaldehydes may also arise by the decomposition of fmctosamine, 
metabolism of ketone bodies, including oxidation of acetone, catalyzed by liver 
cytochrome P450, catabolism of threonine via aminoacetone during diabetic 
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ketoacidosis (Reichard et al, 1986; Tressel et al, 1986; Thornalley, 1999; 
Nakayamae/a/., 2007). 
The increased levels of MG in diabetes and the identification of a number 
of AGEs that are derived from MG make a strong case for the importance of the 
reactive a-oxoaldehyde in the development of diabetic complications (Shinohara 
et al, 1996; Ahmed et al, 1997; Chaplen et al, 1998; Thornalley et al, 1999; Tan 
et. al, 2008). 
Glyoxal, another reactive a-oxoaldehyde and physiologic metabolite, is 
formed by oxidative degradation of glucose, lipid peroxidation or ascorbate 
autoxidation (Wells-Knecht et al, 1995; Malakar et al, 1996; Schwarzenbolz et 
al, 2008). 3-Deoxyglucosone is formed by the degradation/fragmentation 
fructose-3-phosphate (Zyzak et al, 1995; Thornalley et al, 1999; Delpierre et al, 
2000). Increased levels of MG/glyoxal have also been reported in the blood from 
diabetic patients and in the lens of streptozotocin-induced diabetic rats (Philips, 
1993; Mclennan et al, 1994; Lapolla et al, 2000). The maintainence of low levels 
of a-oxoaldehydes is important because they are highly reactive and can bind to 
and modify cellular proteins and nucleic acids (Kalapos, 1999; Thornalley, 2003). 
Exposure of cells to high concentrations of a-oxoaldehydes results in toxicity and 
growth arrest (Thornalley, 1996; Sell et al, 2008). Under hyperglycemic 
conditions, an increase in the MG concentration is seen which is attributed to the 
elevated polyol pathway flux leading to increase in the cytosolic NADH/NAD+ 
ratio. This in turn causes increase in the activity of the glyceraldehydes-3-
phosphate dehydrogenase and hence high concentrations of triose-phosphates 
(Brownlee, 2001; Beisswenger et al, 2003). 
1.1.4. Gly cation of proteins with sugars 
Majority of the investigations on glycation reactions focus on those 
mediated by glucose (glucation), since glucose is the most abundant 
monosaccharide in blood and tissues and its levels are elevated remarkably in 
diabetes (Ghosh-Moulick et al, 2007). A plethora of research is available on the 
reaction of glucose with proteins, nucleic acids and other biomolecules. Glucose 
has been shown to react non-enzymatically with lens crystallins (Stevens et al, 
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1978; Chiou et al, 1981), red cell membrane proteins (Miller et al, 1980), 
peripheral nerve proteins (Vlassara et al, 1981), serum albumin (Dolhofer and 
Wieland, 1979), collagen (Le Pape et al, 1981; Perejda et al, 1982) and several 
other proteins (Suarez et al, 1989). Many of these studies have been carried out in 
vitro but protein glycation has also been established in vivo especially in diabetic 
animals and patients (Suarez et al, 1989). In addition to glucose, other simple 
carbohydrates such as galactose (Urbanowski et al, 2003), sialic acid (McKinney 
et al, 2002), mannose (Zaman and Verwilghen, 1981), glucose-6-phosphate 
(Haney et al, 2003), fucose (Zaman and Verwilghen, 1981) and ribose (Franklin 
and Higgins, 1984) have been shown to readily glycate proteins. 
Detailed studies on protein glycation have shown that ribose is far more 
reactive than glucose or fructose in the Malliard reaction and subsequent 
transformations (Yan and Harding, 1997; Drasla et al, 2002). Monnier and 
Cerami (1989) reported the identification of a fluorescent imidazopyridinium 
compound designated 'pentosidine' on the basis of its apparent derivation from 
ribose, lysine and arginine. The pentosidine concentration increased linearly with 
age in duramater, more significantly in tissue from diabetics and has been 
positively correlated with the presence of retinopathy and nephropathy in diabetic 
patients (Sell et al, 1994). In view of the known low levels of ribose in tissues, it 
was suggested that the pentose arose from oxidative degradation of glucose, 
fructose or ascorbate (Dyer et al, 1991; Grandee and Monnier, 1991). Kalifah et 
al. (1996) observed that glycation of Ribonuclease A by ribose was considerably 
faster than that by glucose, and the rate of AGE formation initially increased with 
increasing sugar concentrations. More recently, studies on accumulation of non-
enzymatic crosslinks on bone collagen were carried out in vitro conditions. It was 
observed that seven days of ribosylation leads to extensive non-enzymatic 
glycation related modification of bone quality as compared to control specimens. 
This suggests that age-related accumulation of glycation adducts in bone may alter 
the organic matrix stiffness and contribute to born fragility (Vashishth et al, 
2003). Also ADP-ribose, generated from NAD by ADP-ribose transfer reactions, 
lead to rapid formation of carboxymethyllysine residues, histone HI dimers and 
highly fluorescent products with properties similar to the glucose derived AGEs. 
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ADP-ribose is more efficient than other pentose donors for glycation and 
glycoxidation of protein amino groups (Jacobson et al, 1997; Frolov et al, 2006). 
1.1.4.1. Glycation with fructose 
Recent years have witnessed a remarkable interest in the in vivo and in 
vitro glycation reactions mediated by fructose (fructation) for a variety of reasons. 
Fructose, also described as the fruit sugar, is a ketohexose and the sweetest among 
the naturally occurring sugars. Fructose is present in high concentrations in fruits 
like apples, berries, dates, figs, grapes, etc. Fructans - the polysaccharides made 
up of fructose, also occur naturally in some foods and have been the principal 
source for large-scale production of the sugar. Being two and a half times sweeter 
than glucose, fructose has emerged as an important sweetener in a variety of foods 
and beverages, especially those targeting the calorie conscious and diabetics. 
Fructose is sometimes advocated as a preferred sweetener for diabetic subjects 
(Gerrits et al, 1993) and also constitutes a major component of non-diabetic diet 
in the form of sucrose. The impressive technologies currently available for the 
conversion of sucrose and corn starch to fructose have made possible the 
manufacture of thousands of tons of fructose, both as high fructose syrup as well 
as that in the pure and crystalline state, quite convenient and inexpensive 
(Hanover et al, 1993). Use of high fructose syrup as the principal sweetener in 
variety of soft drinks has contributed very significantly to the consumption of 
fructose in large quantities, especially by young people. This, together with recent 
emphasis on the inclusion of large portions of fruits and vegetables in diet has also 
resulted in marked increase the consumption of fructose (Park and Yetley, 1993; 
Krajcovicova-Kudalcova et al, 2002). 
Both diet and endogenous synthesis contribute to the intracellular fructose 
concentrations. Fructose can be absorbed from the intestine albeit at rates lower 
than those for glucose but the later facilitates its absorption (Truswell et al, 1988). 
Liver is the main site of fructose metabolism, although some fructose may be 
utilized by the small intestinal mucosa and kidney (Van den Bergh, 1986). In 
some tissues, such as eye lens, kidney and peripheral nerves, a polyol-
metabolizing pathway, is active and is thought to participate in diabetic 
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complications (Perejda and Uitto, 1982). The pathway convert glucose to sorbitol 
by aldose reductase and sorbitol to fructose by sorbitol dehydrogenase [Figure 5]. 
In the human ocular lens, fructose concentration may increase 60-fold compared 
to the control (Kashiwagi et al, 1992). Similar local increases in fructose 
concentrations have also been demonstrated in diabetic-like conditions in 
peripheral nerves, blood vessels, and erythrocytes (Heath and Hamlett, 1976; 
Poulsom et al, 1983; Tomlinson et al, 1985) and testis (Fakuoka et al, 1989) that 
operate the active polyol pathway. In cardiac muscle of diabetic rats, fructose 
concentration may increase 60-fold as compared to the control (Kashiwagi et al, 
1992). 
Sorbitol 
Aldose reductase dehydrogenase 
Glucose ^ ^ *• Sorbitol — y -s. — • F r u c t o s e 
NAOPH NADP+ NAD+ NADH 
Figure 5: The polyol pathway. 
1.1.4.2. A comparison of gly cation by glucose and fructose 
Fructose is far more reactive than glucose in the glycation reactions due 
the presence of higher concentrations of the reactive open chain structures as 
compared to glucose (Bunn and Higgins, 1981). While the glycation with glucose 
leads to the formation of unique products by Amadori rearrangement by which a 
carbonyl group emerges at C-2 position, Amadori rearrangement of the Schiff 
base formed as a result of reaction with fructose appears to follow two alternative 
routes [Figure 6]. The first, in which C-l participates in the Amadori 
rearrangement and generates an aldehyde group at the position and the other, in 
which the keto group is generated at C-3 position. In addition, fructation appears 
to differ from gluction in the high reactivity and rapid rearrangement of the 
Amadori product of the former in Heyns kind of rearrangement (Suarez et al, 
1989; Szwergold et al, 1999). Evidently, the post Amadori products of fructose 
differ significantly from those during glucation and like those of glucose, are 
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highly heterogeneous and complex and yet to be fully characterized (Suarez et al, 
1989; McPherson et al, 1988; Thornalley et al., 1999). 
Fructose is far more susceptible to autooxidation and generates hydroxl 
radicals more readily than glucose as measured by its ability to hydroxylate 
benzoate presumably adding to its ability to modify and damage proteins (Hunt et 
al, 1988; McPherson et al, 1998). 
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Figure 6: The early reactions of proteins with glucose 
and fructose (Miyazawa et al., 1998). 
1.2. Glycation of various bimolecules 
Detailed studies on glycation have shed light on its specificity in the 
reaction of amino groups with various sugars. Glycation of proteins like 
hemoglobin, collagen, low density lipoproteins has shown to induce number 
changes in them such as, exposure of hydrophobic residues and thiols (McDonald 
et al, 1979; Shaklai et al, 1984), conformational and other alterations leading to 
loss of the biological activity in them (Lorenzi et al, 1994; Turk, 2001). 
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1.2.1. Glycation of extracellular proteins 
Realization of the importance of Maillard-like reactions in vivo began in 
the mid 1970s. This started with the studies on hemoglobin A l c (HbAlc), a 
naturally occurring minor human hemoglobin that is elevated in diabetes. HbAlc 
was known to be a post-translational non- enzymatic adduct of glucose with the 
N-terminal valine amino group of the [3 chain of hemoglobin. The measurement of 
the elevation of HbAlc in diabetics allowed the assessment of the degree of 
glucose control integrated over several weeks (Koenig et al, 1976). However, the 
idea that HbAlc was a Schiff base was troubling, since Schiff bases are generally 
hydrolytically unstable. Subsequent work (Koenig et al, 1977) revealed that the 
carbohydrate in HbAlc w a s attached as a 1-deoxy-l-fructosyl residue to the N-
terminal valine nitrogen, derived from an initially formed Schiff base via a 
chemical transformation known as the Amadori rearrangement (Hodge, 1955).The 
glycation of hemoglobin increases its oxygen affinity and makes it more 
susceptible to oxidation (Bucala et al, 1993; Saudek et al, 2005). 
Albumin is the most abundant protein in plasma and comprises about 60% 
of the total protein found in blood (Shaklai et al, 1984). Human serum albumin 
(HSA) is meant for maintaining osmotic pressure in the circulating system (Peters, 
1996) and also plays protective role as antioxidant (Coussons et al, 1997). HSA 
has highly flexible structure so that it can bind various molecules for their 
transportation throughout the body. Glycation of albumin occurs at multiple sites. 
Glucose can be attached to Lysl99, Lys281, Lys439 and Lys 525 as well as at 
some other lysine and arginine residues and also at the N-54 terminal residues of 
the polypeptide (Iberg and Fluckinger, 1986). Lysine-199 is one of the major 
glycation sites of HSA (Iberg and Fluckinger, 1986). In diabetes, the level of 
glycated HSA rises from 6-10% to 20-30%). HSA can potentially undergo non-
enzymatic glycosylation on some of its 58 lysine residues (Guthrow et al, 1979). 
As a result, glycated albumin has been proposed as a useful marker for short term 
monitoring of the diabetic patients (Williams and Siegel,, 1985). Glycated 
albumin is preferentially transported across the glomerular filtration barrier 
(Williams et al, 1981; Williams and Solenski, 1984; Williams and Siegal, 1985), 
the glomerular mesengial and epithelial cells exhibit an enhanced uptake of 
12 
glycated albumin that is accompanied by an increase in production of cell 
hydrogen peroxide (Agarwal and Daniels, 1992; Daniels et al, 1993; Wa et. al, 
2007). The pathobiologic events induced by glycated albumin include increased 
expression of interlukin (IL)-8 and nitric oxide synthetase as well as nitric oxide 
production in endothelial cells (Amore et al, 1997; Bain et al, 1998), genes 
activation of protein kinase C (PKC), the mitogen activated protein kinase 
(MAPK) cascade, the nuclear factor (NF)-KB and increased expression of the 
inflammatory cytokines like monocyte chemoattractant peptide (MCP-1) and IL-6 
in vascular smooth muscle cells (Hattori et al, 2001; Higai et al, 2008). Glycated 
albumin has also been shown to increase oxidative stress, phosphorylation of 
extracellular signal regulated kinase (ERK), nuclear translocation of NF-KB in 
monocytes-macrophages (Cohen et al, 2003; Sattarahmady et al, 2007), 
activation of signaling pathways and upregulation of growth factor systems. 
The most important building block in the entire animal world, collagen 
constitute the tie that binds the animal kingdom together (Tsilibary et al, 1988). It 
is the major insoluble fibrous protein in the extracellular matrix and in connective 
tissue. There are at least 16 types of collagen, but 80-90 percent of the collagen in 
the body consists of types I, II and III, though they all serve the same purpose, to 
help tissues withstand stretching (Yang et al, 1995).Collagen has a very low 
turnover rate and is a prime target of glycation by glucose. In line with its unique 
functional importance, glycation and glycoxidation of collagen have been 
implicated in the cumulative development of microvascular complications 
observed in patients with long-term diabetes mellitus (Wolff et al, 1991; Lapolla 
et al, 1994). Preferential glycation sites along the collagen a-chains were 
proposed, giving rise to an uneven distribution of glucose adducts (Reiser et al, 
1992). Glycated collagen has been shown to react with other collagen molecules 
or with other plasma proteins (e.g. immunoglobulin, LDL) presumably through 
AGE crosslinking reactions (Brownlee et al, 1983). This crosslink formation 
appears to contribute towards the development of atherosclerosis and coronary 
disease, kidney damage, retinal pathology, poor peripheral circulation and other 
lesions (Sims et al, 1996). During formation of normal collagen fibrils, some 
collagen lysine residues and hydroxylysine residues are oxidized by lysyl oxidase, 
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which converts their s-amino groups to aldehydes. These aldehydic groups react 
with lysine or hydroxylysine residues of adjacent collagen molecules in the fibrils 
resulting in the formation of crosslinks (Yue et al, 1983). This process is self-
limiting in that lysines in closely crosslinked collagen molecules are no longer 
sterically accessible to lysyl oxidase. Evolution appears to have tailored this 
process to produce collagen fibrils with an optimal balance of strength and 
flexibility (Kohn et.al, 1984). Unfortunately, AGE crosslinking, being mediated 
by small molecules, is not subject to such limitations and can proceed even in 
mature collagen molecules. AGE-mediated overcrosslinking of collagen 
molecules to each other causes loss of bulk elasticity and flexibility and increased 
brittleness (Craig et al, 2008). Raabe et al. (1996) observed that carbohydrate-
induced modifications apparently have a major impact on molecular conformation 
and decreased thermal stability of the collagen IV molecules which they later 
proposed to be the molecular basis for pathophysiological changes in both cell-
matrix interactions and matrix assembly which were observed for basement 
membranes in diabetic microvascular complications. 
There is evidence that glycation play a role in abnormal amyloid 
aggregation in Alzheimer's disease (Andreasen and Zetterberg, 2008). Amyloid 
plaque material like that from Alzheimer's disease patients is also found in low 
quantity in age-matched human controls. Analysis of plaque material revealed that 
the plaque from Alzheimer's disease patients had three times more AGE content 
per milligram amyloid as compared to the amyloid from controls (Vitek et al, 
1994; Burdo et al, 2008). The persisting plaque undergoes AGE crosslinking, 
gaining further resistance to proteolytic degradation and removal processes. In 
vitro studies have found that formation of insoluble, fibrillar aggregates from 
AGE-modified (3-amyloid peptide was much faster than for control P-amyloid 
peptide (Lederer and Klaiber, 1999; Takeuchi and Yamgishi, 2008). 
1.2.2. Glycation of cellular proteins and enzymes 
Although extracellular proteins are more susceptible to glycation, several 
intracellular proteins have also been shown to undergo glycation in vivo. For 
example, the eye lens crystallin are very long lived protein, possibly lasting an 
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entire lifetime and hence experience prolonged exposure to sugars. Although 
crystallins have evolved to retain optical clarity for extended periods, yellow-
brown pigments with the spectral and fluorescent properties of AGEs are formed 
in the lens as a function of age (Monnier and Cerami, 1981). These pigments can 
undergo further reactions, turn dark in colour and contribute to the formation of 
cataracts. Glucose and other sugars have been shown modify amino groups in 
crystallins, causing conformational changes and expose previously buried 
sulfhydryl groups, which can then autoxidize to form intermolecular disulfide 
bonds (Monnier et al, 1979). The resulting disulfide-linked superaggregates can 
be of sufficient dimension to scatter light and produce a cataract. A residual 
amount of protein crosslinking has been however shown to be present that is not 
disulfide related (Harding, 1973, Salim et al, 2003). AGEs may be directly 
implicated in this crosslinking (Ahmed et al., 2003; Abraham et al, 2008). 
Glycation has been shown to cause modifications that effect the catalytic 
activity of various enzymes. Several important enzymes are known to undergo 
remarkable glycation-induced loss of biological activity and thus the mechanism 
is receiving considerable attention (Arai et al, 1987). Sugars induce inactivation 
of enzymes in numerous ways; they modify the active site residues or react with 
residues distinct from active site causing more subtle and complex mechanisms 
including compaction, loss of protein flexibility, protein aggregation etc. (Seidler, 
2005). Cu, Zn-Superdismutase (Cu,Zn-SOD) constitute the first and the most 
important line of antioxidant defense, particularly against superoxide radicals 
(Choudhary et al, 1997; Takamiya et al, 2003). Glycation has been shown to 
cause the enzyme covalent crosslinking associated with loss of enzymatic activity 
and release of copper ions (Arai et al, 1987; Kang, 2003). Earlier studies on two 
important antioxidant enzymes catalase and superoxide dismutase by Yan and 
Harding (1997) showed that their ready inactivation on in vitro glycation with 
various sugars. 8-Aminolevulinic dehydratase, an enzyme involved in heme 
biosynthesis has been shown to be inactivated by fructose and several other 
pentoses and hexoses (Cabellero et al, 1998). A detailed review by Seidler (2005) 
show that glycation-induced alterations bring about inactivation of a number of 
enzymes. Other enzymes known to undergo drastic inactivation by various sugars 
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include, malate dehydrogenase (Heath et al, 1996), alanine transferase (Yan and 
Harding, 2003), esterase (Beranek, 2001), isocitrate dehydrogenase (Kil et al, 
2004) and glucose-6-phosphate dehydrogenase (Ganea and Harding, 2005). 
1.2.3. Glycation of DNA 
The DNA bases, adenine, cytosine and guanine have free amino groups 
that are potential sites for glycation and AGE formation. Among the nucleotides 
deoxyguanosine appears to be most reactive under physiological conditions 
(Pischetsreider et al, 1999; Thornalley, 2003; Li et. al, 2008). Eukaryotic DNA is 
however protected from glycation by the nuclear membrane and also adequately 
shielded by histones, nonhistone proteins and polyamines with the abundant 
nucleophilic groups (Lee and Cerami, 1991). Available evidences however 
suggests that sugars and several electrophilies that can glycate DNA gain access 
for reaction with DNA in vivo (Mistry et al, 2003; Bidmon et al, 2007; Fleming 
et. al, 2008). Histone glycation can also cause damage by a variety of 
mechanisms including the generation of reactive oxygen species in viscinity 
(Pischetsrieder et al, 1999; Baynes, 2002). The damage can occur in the form of 
single stranded breaks as well as in depurination (Li et al, 2008). The damage to 
the DNA is normally silent since fraction of bases modified is small and those 
modified may be excised and replaced. While DNA repair occurs with high 
fidelity, it is clearly not error free and the glycation reactions may end up in 
alterations in base sequence and gene integrity (Li et al, 2008). 
Several nucleotide adducts from glycated DNA have been identified The 
nucleotide AGEs characterized include N2-(l-carboxyethyl)-guanine (Papoulis et 
al, 1995), 5-glycolyldeoxycytidine (Kasai et al, 1998), N2-7-bis(l-hydroxy-2-
oxopropyl)-2-deoxyguanosine (Schneider et al, 1998; Thornalley, 2003) [Figure 
7]-
Evidence has been found that in vivo AGE formation in mammalian cells 
DNA may be responsible for insertions containing repetitive sequences of the Alu 
family that have been found to disrupt several human genes (Bucala et al, 1993). 
Nucleotide glycation and the resulting effects are expected to and indeed are most 
marked in diseases like diabetes and uremia in which sugars and other glycating 
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agents accumulate in high concentrations. Such accumulation may be a possible 
cause of congenital malformations in infants of poorly controlled, insulin-
dependent diabetic mothers (Lee et al, 1995; Thornalley, 1999; Brever et al, 
2008; Dutta et. al, 2008). 
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Figure 7: Structural formulae of the major nucleotide AGEs (Thornalley et al, 2003). 
1.3. AGE receptors and AGE removal 
AGEs exert their pathological effects either directly or by interaction with 
specific cell surface receptors. Scavenger receptors with high affinity for AGEs 
have been identified on many cells including macrophages and barrier cells 
(Esposito et al, 1989; Sholnik et al, 1991). Among these, the best known and 
characterized is RAGE (receptor for AGE) (Vlassara et al, 1985; Vlassara et al, 
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1994; Toth et. al, 2007). RAGE is a 35 kDa a protein that has been isolated and 
cloned from the bovine lung. RAGE is a member of the immunoglobulin 
superfamily and is expressed on the surface of various cells such as monocytes, 
macrophages, mesangial cells, several neurons, endothelial cells, smooth muscle 
cells and fibroblasts. The receptor is responsible for the activation of intracellular 
signal transduction pathways including ERK kinase, p38mapk, JNK kinases and 
nuclear factor kB (NF-kB) pathway (Simm et al, 2004; Yamagishi et. al, 2006). 
The AGE-RAGE interaction results in the stimulation of the transcription of 
cytokines and growth factors genes (TNF-a, IL-1, PDGF, IGFI, Interferon y), 
adhesion molecules (ICAM-1, VCAM-1), stimulation of cell proliferation, 
increase of vascular permeability and induction of migration of macrophages 
(Bierhaus et al, 1998; Kislinger et al, 2002; Toth et. al, 2008). 
1.4. Immunoglobulins 
Immunoglobulins (Ig) are soluble antigen binding glycoproteins, present 
on the B-cell membrane and secreted by plasma cells. They contribute specially to 
immunity and protection in response to the presence of a foreign substance 
(Porter, 1959; Kabat and Mayer, 1961). 
Immunoglobulins posses two distinct type of polypeptide chains that are 
linked both by covalent bonds and non covalent interactions (Milstein and Pink, 
1970). The smaller light chain (MW 25,000) is characterstic of the members of 
whole group of proteins and is in turn of two types- kappa (K) and lamda (X). The 
larger heavy chain (MW 50,000-77,000) is specific for each class. Based on 
antigenic as well as structural properties of the heavy chain, the immunoglobulins 
are classified as IgG, IgA, IgM, IgD, IgE [Figure 8] (Gonzalez-Quintela et. al, 
2003). The heavy chains of each class are designated by Greek letters y, a, \i, 8 
and s respectively Amino acid sequencing of immunoglobulin heavy and light 
chains showed that both chains contain several homologous units of about 110 
amino acid residues containing interchain disulphide bonds approximately 60 
residues apart (Kabat et al, 1970). The first or the N- terminal domain on both 
light and heavy chain is highly variable in terms of amino acid sequence and is 
designated as VL and VH accordingly (Hood and Talmage, 1970). The subsequent 
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domains on both chains are much more conserved in amino acid sequence and are 
designated CL or CHI , CH2 and Cn3. The major function of VL and VH domains is 
to constitute the antigen binding site. The region between CHI and CH2 domains 
containing the interchain disulphide bonds is known as the hinge region 
(Stanworth and Turner, 1986). Flexibility in the hinge region permits the two 
antigen binding sites to operate independently. The principal immunoglobulin 
classes show some characterisitic features as detailed in Table I. 
Secretory Piece J Chain 
Figure 8: Schematic representation of overall structures of the five 
major classes of secreted antibodies. 
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1.4.1. Glycation of Immunoglobulin G 
IgG is the predominant immunoglobulin in blood lymph, cerebrospinal 
fluid and peritoneal fluid. The four chain structure of IgG was proposed by Porter 
(1959) and its complete sequence elucidated by Edelman (1969). IgGs are 
multimeric proteins with a molecular weight of about 150 kDa a corresponding to 
a sedimentation coefficient of 7S. IgG is made up of 2 heavy gamma (y) chains 
and 2 light chains, either kappa (K) or lambda (X) linked together by disulphide 
bonds [Figure 9] (Saphire et. at, 2002; 2003). 
The constant region of the gamma chain is constructed from three 
homologous units designated CHI, CH2 and Cu3 and contains a stretch of 
aminoacid residues between CHI and CH2 in the hinge region which shows no 
sequence homology with any of the homologous units. The region is rich in 
proline residues but also contains the cysteines that link the two heavy chains 
together (Edelman et ah, 1970). The region is highly suspectible to for proteolytic 
cleavage, as the amino residues in this region are exposed to the surrounding 
medium. 
V H il< >mJIII 
Antigen-binding site 
\'H ill mum 
/ 
Y'L idmI.IIII 
Antigen-binding site 
V'L domain 
(artxihydrale chain 
lltravv chains 
Q|3 
Figure 9: Schematic representation of three dimensional structure of immunoglobulin 
molecule (Silverton etaL, 1977). 
In vivo glycation of immunoglobulins is of special concern because it has 
the potential to affect the functionality, influence immunological response and 
overall immunocompetence. Impaired resistance to infections has long been 
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associated with uncontrolled diabetes (Gilger, 1986; Jelinek, 1986; Moutschen et 
al, 1992). While the exact mechanism of enhanced susceptibility of diabetics to 
infections is incompletely understood, potential candidates include 
immunoglobulins that contribute towards the humoral immunity. 
Available evidences suggest that glycation of IgG, IgA and IgM is 
enhanced in the blood of diabetics (Danze et al, 1987; Kaneshige, 1987), with 
IgM glycated at a rate 3-6 times that of IgG and IgA (Zoppi et al, 1990; Hammes 
et al, 1990). Factors like molecular size, number of binding sites for sugar and the 
pattern of release in circulation during an immune response may contribute 
towards their relative enhanced rates of glycation (Ardawi et al, 1994). 
In order to locate precisely the fragment(s) that are prefentially glycated, 
Menini et al. (1992) performed concanavalin A-Sepharose affinity 
chromatography of the tryptic fragments derived from IgM molecule. The affinity 
support was chosen on the basis that IgM is one of the extensively glycosylated 
plasma proteins, with five glycan attached chains on the u subunits, that strongly 
bind to concanavalin A (Weinstein et al, 1972). It was shown that glycation 
occurs prefentially on the Fd region of u chains suggesting the possibility of 
alteration of biological activity of the immunoglobulins (Hammes et al, 1990). 
Hammes et al, (1990), also investigated the glycation of serum IgM of 
diabetic patients of blood 'O' groups. In the patients, both anti-A and anti-B 
agglutinins were of the IgM-isotype. The glycated and non-glycated fractions 
were separated using boronic acid affinity chromatography and tested against 
group Al erythrocytes. Agglutination which is mainly an IgM-mediated-reaction 
was significantly lower in the glycated fraction as compared to that observed with 
non-glycated fractions. It was suggested that additional glucose molecules 
attached non-enzymatically to the antigen-binding sites of IgM might bring about 
physiochemical imbalances resulting in the decrease antigen recognition 
(Brownlee et al, 1989). A part of the disturbing effect of non-enzymatic glycation 
in circulation might however be offset through newly synthesized IgM subsequent 
to infection. Apparently in the initial phase of an acute infection in diabetes 
mellitus the glycated IgM might contribute to a certain extent, to the observed 
defective host resistance. The pathological explanation for the difference in the 
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way diabetic patients with good metabolic control and normal individuals respond 
to infections in comparison to diabetic patients with poor metabolic control may 
be in lower level of glycation of immunoglobulin in the former (Hammes et al., 
1990).Thus, the impaired IgM function in diabetes mellitus may have more 
serious consequences for host resistance in the early phase of infection. 
Several studies have also shown that serum IgA concentrations increases 
over normal non-diabetic values in diabetic patients. Like with other serum 
proteins, IgA also undergoes glycation in vivo, the extent of which being a 
function of the glycaemic history and the rate of turnover (Alberti et al, 1990; 
Duncan and Heiss, 1984; Kennedy and Baynes, 1984). Earlier studies have shown 
evidence of glycation of IgA and the presence of IgA-albumin complexes even 
under average glycemia (Fujita and Sakururabayashi, 2001). However, Fujita et 
al, (2003) carried out studies to analyze glycation of IgA in patients with 
monoclonal proteinemia and in those with polyclonal hyper-IgA. They observed 
that complex formation of IgA with albumin plays a major role in the glycation of 
IgA (Fujita et al, 2003). Results showed that IgA that was not associated with 
albumin and was not glycated, although the glucose concentrations in the patients 
serum was high. Thus, binding to albumin appears to be a major factor in the 
glycation of IgA. Because half-life of albumin is longer (15-19 days) (Kerr, 1990) 
than the half-life of human IgA (6 days) (Austin, 1987), IgA bound to albumin 
may remain in circulation longer, increasing the possibility of its glycation (Fujita 
era/., 2003). 
In view of the long circulating life and predominant role in immune 
protection, IgG glycation has attracted far greater attention as compared to that of 
other immunoglobulins. In addition, IgGs are rich in lysine and arginine making 
then highly potential protein glycation targets (Vrdoljak et al, 2004). 
In order to characterize the level and the sites of glycation on IgG, Danze 
et al. (1987) used affinity columns of phenylboronate for samples from both 
normal and diabetic subjects. Their studies showed significant amounts of IgG 
being retained on the columns from diabetics as compared to non-diabetics. Also a 
low but significant inverse correlation was found between glycated IgG and total 
IgG in diabetics: patients with low serum levels of IgG have more glycated IgG 
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than those with high serum IgG levels. This variation in glycated IgG could be 
due only to the variation in the ratio glucose/IgG (i.e. a low IgG will give a high 
glucose/IgG ratio) but in addition, differences in the turn-over of IgG may play an 
important role. Furthermore, studies on isolated fragments (F(ab)> or Fc') from 
IgG gave an indication on the sites of glycation. Differences in the glycation 
between IgG from diabetic and non-diabetics were related mainly to differences in 
the F(aby part of the IgG molecule. Taken together the results suggested that the 
principal site of glycation is within Fab" (and probably the Fd) of the IgG. It was 
noteworthy that Fab" does not contain the complex carbohydrate, (which is 
located in Fc') which may contribute towards the affinity of intact IgG for 
boronate agarose gels. 
Another study has however showed that both the heavy and the light chain 
of IgG are susceptible to glycation and the 60 amino acid long hinge region, 
which is unique to IgG3 and rich in lysine and arginine residues is most 
susceptible (Tai and Newkirk, 2000). 
Using MALDI/MS and computer molecular modeling, Lapolla et al. 
(2000, 2001, 2004, 2005, and 2006) investigated the nature of IgG glycation. 
MALDI data on intact proteins could determine the total number of glucose 
molecules condensing on IgG, but they were unable to identify the glycation sites 
responsible for the possibly altered activity of Fab' and/or Yc components of 
glycated IgG. For such identification, experiments were carried out on enzymatic 
digestion of IgG with papain. The studies suggested that while twenty glucose 
molecules condense on the Fab' portion of IgG, only ten reacted with the Fc\ 
Computer molecular modeling of IgG revealed that the 82 lysine residues present 
in the molecule are uniformly distributed on the Fab" and Fc' fragments. In 
theory, all the s- amino groups of these lysine residues maybe the targets for non-
enzymatic addition of glucose. Experimental MALDI data however indicated that 
not all the lysine residues react readily with the sugar. It was assumed that the 
lysines most reactive towards the glucose were those which were more exposed 
[Figure 10]. In agreement with the experimental findings, their distribution on the 
IgG molecule suggested that the Fab" fragments are more prone to attack by 
glucose, particularly in their light and heavy variable regions (VL and CL). It is 
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well recognized that these regions play an important role in the process of 
molecular recognition between antibody and antigen. 
Both MALDI/MS and molecular modeling yielded important information 
that suggests that immunodeficiency observed in some diabetic patients may be 
explained, at molecular level, to the prefential and more extensive glycation of the 
Fab' regions of IgG, and consequently to the impairment inhibition of molecular 
recognition between antibody and antigen. 
(a) (b) 
Figure 10: Distribution of lysine residues on IgG molecule. 
(a) a-carbon trace of IgG and 82 lysine residues present in structure randomly 
distributed on F(ab)" and Fc" fragments of antibody molecule. 
(b) Most solvent-exposed lysine residues colour-coded according to the range of 
solvent-accessible surface (SAS, A°2). Only half molecule of IgG is shown because 
of its molecular symmetry. Yellow lysine residues, with highest SAS values, are 
first glycated, then red, green and violet ones. Their distribution on the IgG 
molecule shows that F(aby fragment is extensively attacked by glucose (LapoIIa et 
ah, 2001). 
Vrdoljak et ah (2004) carried out in vitro glycation of human IgG using D-
[U-C ]-glucose under pseudophysiologic and psuedodiabetic conditions as well 
as under condition used for preserving immunoglobulin solutions for intravenous 
administration. They also measured glycation under pasteurization conditions 
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60°C. The radiolabel was distributed uniformly on human IgG, without any 
preference for Fab" or Fcf fragments under all tested conditions. 
Reports on the effects of glycation on function of the Fc' region of IgG are 
similarly contradictory. The first proposal that glycation impairs biological 
function of IgG was made by Dolhofer et al. (1985). In vitro incubation of human 
and rabbit IgG with glucose in their study lead to covalent incorporation of the 
sugar into the protein and loss in complement fixing activity at glycation levels 
well comparable to those found in blood proteins of diabetics. 
Morin et al. (1987) glycated in vitro mouse monoclonal and goat 
polyclonal antibodies used in the measurement of human ferritin, thyrotropsin and 
transferrin by ELISA and compared the calibration curves prepared utilizing 
glycated and non-glycated antibodies. Glycation of the monoclonals was 
confirmed by borate affinity chromatography and assay with thiobarbituric acid 
reagent. No evidence however emerged that suggested impairment in antigen 
binding by glycated antibodies, providing no support to the idea that glycation 
may be an important contributory factor in the decreased resistance of diabetics to 
infection. 
In a subsequent study, Morin et al. (1989) compared the immunoreactivity 
of glycated and non-glycated human IgG and IgM raised against rubella and 
infectious mononucleosis by measuring their binding to respective antigens as 
well as for their complement-fixation properties. The study suggested that 
glycated immunoglobulins do not have impaired ability to either bind to the 
antigen or in complement fixation. 
Dolhofer-Bleisener and Gerbitz (1990) carried out antigen binding studies 
on in vitro glycation of human immunoglobulin G, using rabbit antihuman-
albumin IgG but also found no impairment in antigen-antibody aggregate 
formation. They however observed a clear decrease in FcN function like binding to 
protein A and complement fixation at a level of glycation of the immunoglobulin 
commonly found in diabetics. Interaction of IgG with protein A and fixation of 
complement is dependent on the integrity of the region 230-270 of the heavy 
chains (Turner et al, 1969; Pink et al, 1970). They speculated that lysine residues 
246 and/or 248 (Edelman et al, 1970), undergo glycation leading to changes in 
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charge of the immunoglobulin and/or conformation leading to impaired binding of 
complement and protein A. 
Hennessey et al. (1991) analyzed the effects of short-term hyperglycemia 
on the antimicrobial immune function i.e. the ability of IgG to fix complement. 
For this purpose anti-humanalbumin, anti-horseferritin and anti-alkaline 
phosphatase was incubated with various concentrations of glucose and analysed 
for the degree of glycation using thiobarbituric acid assay and for complement 
fixation ability. The findings substaintiated the observations of Dolhofer-Bliesener 
and Gerbitz (1990) that a significant reduction occurs in complement fixation by 
IgG on incubation with high glucose concentrations. 
Sasaki et al. (1993) incubated mouse monoclonal antibody (64 M-2, 
specific for ultraviolet damaged DNA) with various concentrations of D-glucose. 
Glycosylated antibodies were then assayed for their ability to bind to antigen by 
ELISA. In vitro glycation of antibody, specially at the 8 lysine sites in the variable 
region of the heavy chain, was shown to impair the ability to bind to the antigen. 
These findings were in agreement with those of Kaneshige (1987) who observed 
an apparent decrease in anti-streptolysin titres after in vitro glycation of purified 
antibodies with glucose. 
Kennedy et al, (1994) using monoclonal mouse anti-humna-IgG 
antibodies investigated the effect of glycation on their kinetics and affinity of 
antigen binding. Using surface plasmon resonance and ELISA-based methods, 
they observed that glycation significantly increased the rate of dissociation (kdiss) 
as well as the equilibrium dissociation constant (Kd) of the antigen-antibody 
complex, thus destabilizing it. They postulated that the fall in pK of amino groups 
within the antibody due to glycation, or conformational changes occurring in the 
IgG as a consequence of the binding of sugar residues, increases the repulsion 
between the antibody-bound antigen and the monoclonal antibody, thereby 
increasing KdiSS- This study provided convincing evidence that in vitro glycation 
may significantly lower the affinity of an antibody for its antigen. 
Goodarzi et al. (2004, 2005) further, provided evidence on the functional 
alteration of glycated IgG resulting from glycation. Purified human IgG were 
glycated with various concentrations of glucose for different durations. Using 
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anti-human IgG in an electroimmunoassay and single radial immunodiffusion 
system they showed that glycation significantly decreases the mobility of IgG. 
They postulated that in vitro glycation of IgG leads to structural changes in the 
molecule leading to alteration in its mobility in the electroimmunoassay. It was 
suggested that the alteration may contribute to the weakness of its interaction with 
anti-human IgG. They suggested that IgG glycation may play an important role in 
the susceptibility of diabetic patients to infection. 
Thus, impairment of antibody function in combination with other known 
consequences of glycation on components of the immune system may thus play an 
important role in increasing the susceptibility to infection of patients with diabetes 
mellitus. 
1.5. Protection against glycation 
1.5.1. Natural defense 
Several humoral and cellular defense mechanisms that protect various 
tissues from accumulation of AGEs and deleterious effects of glycation reactions 
exsit. Enzyme systems involved in the process include the glyoxalase system (I 
and II), aldehyde reductase, aldose reductase and the liver enzyme, a-
ketogluteraldehyde dehydrogenase (Thornalley et al, 2003). Macrophages possess 
receptors that facilitate recognition and removal of AGE-proteins by endocytosis 
(Vlassara et al, 1985). Various endogenous antioxidants also protect the cells 
against glycation-derived free radicals, while transport proteins like ceruloplasmin 
can bind transition metals such as cupric ions and restrict their participation in 
autoxidative glycation or glycoxidation reactions. 
A novel class of deglycation enzymes have been discovered recently, that 
recognize Amadori products and decompose them (Wiame et al, 2005). So far 
two categories of deglycation enzymes have been identified; fructosyl amine 
oxidases and fructosyl amine kinases. Both act on the Amadori product but differ 
in their mechanism of action. Fructosyl amnie oxidases belongs to a group which 
oxidize the Amadori product of glucose with protein and generate H2O2. The 
Amadori product after oxidation decomposes spontaneously via hydrolysis. 
Fructosamine kinase phosphorylates Amadori products, generates fructose-3-
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phosphate (Mormier and Xinle, 2003). However, the efficiency of these natural 
defenses against gfycation and AGEs in vivo is unknown. 
1.5.2, Synthetic and natural inhibitors 
Considering that glycation contributes remarkably to complications 
associated with diabetes and several other disorders, design and discovery of 
inhibitors of the glycation reactions should offer a promising therapeutic approach 
for the prevention of complications associated with the disorders. Currently, 
several strategies are being employed to control protein glycation. These include 
inhibition of AGE formation and conversion of post Amadori intermediates to 
AGEs, formation of cross-link inhibitors and manipulation of AGE receptor 
pathways are also being investigated (Stitt, 2003; Takeuchi et. ah, 2004) 
[Figure 11]. 
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Figure 11: Potential sites where pharmacological compounds can act 
to inhibit protein glycation (Ahmed, 2005). 
A number of AGE inhibitors have been proposed and grouped on the basis 
of their mechanism of action (Peyroux and Sternberg, 2006). One such group of 
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inhibitors include compounds like DETAPAC, EDTA and phytate that act as 
chelators thereby, sequestering hydroxyl and other free metals ions (Wells-Knecht 
et al, 1995). Many transition metals have important physiological functions and 
their complete removal may however have undesirable consequences. 
The second group comprises of antioxidants that protect cells against 
biomolecular glycation-derived free radicals. Vitamin E has been shown to reduce 
levels of glycated hemoglobin and accumulation of AGEs in arterial walls of 
diabetic patients (Ceriello et al, 1999). There is growing interest in natural 
products with combined anti-glycation and antioxidant properties as they may 
have fewer toxic side effects. Indeed, a number of plant derived flavonoids 
including rutin, quercetin with known antioxidant activity have been reported to 
inhibit glycation, at least in vitro (Asgary et al, 1999; Rout and Banerjee, 2007). 
The third group of inhibitors compete with reducing sugars and modify 
free amino groups, thereby prevent sugar attachment to protein and other 
biomolecules. These include pyridoxal-5'-phosphate and aspirin (Harding, 1985; 
Hadley et al, 2001). Yet another group of AGE inhibitors divert sugars from 
Maillard reaction, but act on more than one step of the complex glycation cascade. 
Aminoguanidine falls under this group as it reacts as a hydrazine with the 
carbonyl group of glucose (Hirsch et al, 1995; Khatami et al, 1998; Reddy and 
Beyaz, 2006). 
Some inhibitors like L-arginine and aminoguanidine trap dicarbonyl 
intermediates to form substituted triazines (Hirsch et al, 1992; Price et al, 2001). 
Amadorins, are the compounds with potential to scavenge post-Amadori products, 
inhibiting the conversion of glycation intermediates to AGEs like pyridoxamine 
(vitamin B6 derivative) (Harding, 1985; Glomb and Monnier, 1995; Lehman and 
Ortwerth, 2001; Voziyan et al, 2003). Some inhibitors are directed towards 
Amadori adducts of proteins like anti-glycated albumin monoclonal antibodies 
(Cohen and Hud, 1989). 
AGE crosslink breakers disrupt the crosslinks between the protein 
molecules, these include like phenacylthiazolium bromide (PTB) and ALT-711 
(Wolffenbuttel et al, 1998; Vasan et al, 2003; Reddy and Beyaz, 2006). 
Compounds capable of blocking the interaction between AGEs and RAGE have 
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also envoked considerable interest. Such compounds could bind inactivate either 
AGEs or RAGE preventing their interaction or by inhibition of the intercellular 
signaling following interaction of AGEs with RAGE. RAGE can be blocked by 
useage of soluble RAGE (Srage), which is the extracellular ligand-binding domain 
of RAGE or by use of antibodies capable of reacting with RAGE (Bucciarelli et 
al, 2002; Abe et al, 2007). 
Molecular chaperones are also being investigating for possible protective 
role against glycation-induced alterations (Ganea and Harding, 1996; Yan and 
Harding, 2003). Molecular chaperones not only assist protein folding but also 
stabilize proteins and prevent their aggregation (Hedrick and Hartl, 1993; Becker 
and Craig, 1994). Derham and Harding (2002) demonstrated that entrapment of 
enzymes inside resealed human erythrocyte ghosts provides them with a more 
physiological environment and stimulates in vivo conditions. Incubation of 
erythrocyte-ghosts-entrapped catalase, malate dehydrogenase, glutathione 
reductase, aldehyde dehydrogenase, lactate dehydrogenase with fructose resulted 
in their inactivation which was remarkably rapid than in vitro conditions. 
Inactivation of enzymes was restricted by inclusion of a-crystallin. Lens structural 
protein, a-crystallin is a molecular chaperone that protects glycation-induced 
inactivation of enzymes like glucose-6-phosphate dehydrogenase, malate 
dehydrogenase and esterase (Ganea and Harding, 1996; Heath et al, 1996; Yan 
and Harding, 2003). When incorporated into red cell ghosts a-crystallin also 
protects the membrane enzyme Na/K-ATPase against glycation and preserves its 
activity upon exposure to fructose or H2O2. It is believed that a-crystallin acts 
through dynamic interactions, such that the chaperone may prevent the further 
unfolding that accompanies the initial reaction with sugars (Derham el al, 2003). 
Furthermore, a number of naturally occurring small organic molecules 
primarily involved in maintaining osmotic pressure in the cell, display chaperone-
like activity stabilizing the native conformation of proteins and protecting them 
from various kinds of stress (Derham et al, 2003). In addition, these small organic 
stress molecules may regulate the activity of some molecular chaperones, and 
stabilize the folded state of some proteins whose misfolding contribute towards 
diseases, such as Alzheimer's and Parkinson's diseases, alpha-1-antitrypsin 
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deficiency and cystic fibrosis. The compounds however have no substrate 
specificity comparable to molecular chaperones, but some have been shown to be 
specific in stabilizing few proteins. For example, 6-aminohexanoic acid 
significantly protects glucose-6-phosphate dehydrogenase against glycation-
induced inactivation by trehalose and by guanidinum hydrochloride (Ganea and 
Harding, 2005). 
Similarly, the role of antibodies as molecular chaperones has been the 
latest forte for exploration by researchers. Studies show the potential of the 
antibodies and monomeric Fab" fragments in protecting the inactivation and 
aggregation of Cu,Zn-Superoxide dismutase by various sugars and far more 
reactive dicarbonyl compounds, glyoxal/methylglyoxal (Jabeen et al, 2007; 
Jabeen et al, 2006 a&b). Although the exact mechanism for the protective role of 
antibodies needs to be elucidated, earlier studies have found that antibodies may 
act as chaperones under specific conditions and can facilitate folding and prevent 
aggregation of protein antigens (Ermolenko et al, 2004). Several explanations 
have been suggested to explain the protective effect of antibodies. Ermolenko et 
al (2004) suggested that owing to their large size antibodies may sterically hinder 
the aggregation upon binding to the antigen molecules. Alternatively, binding of 
antibodies may shift equilibrium between unfolded and native conformations of 
the protein antigen towards the native form or lower the activation barrier through 
stabilization of the folded transition state (Hendrick and Hartl, 1993). Earlier 
studies on some monoclonal antibodies have shown that they bind at strategic 
protein-folding initiation sites, leading to the correct refolding of clustered 
epitopes (Solomon and Schwartz, 1995). Also, antibodies raised against the liable 
region of RNase were more protective and imparted stability to RNase on binding 
as compared to the polyclonal antibodies raised against the enzyme (Younus et al, 
2001). 
1.6. Anti-AGE-antibodies 
Owing to deleterious effect of glycation on different molecular 
components of the body, studies have been carried out over the years to produce 
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antibodies against glycated proteins so that convenient, sensitive and accurate 
assessing procedures could be developed. 
Cohen and Hud (1989) presented the first hybridoma secreting monoclonal 
antibody raised in mice against unreduced glycated albumin which is the 
physiologic form that occurrs in vivo. They brought about the fusion of SP2/0 
myeloma cells with spleen cells from BALB/c mice immunized with unreduced 
glycated albumin isolated from human plasma. The specificity of monoclonal 
antibody was demonstrated by immunoblotting and by ELISA, wherein the 
monoclonal antibody reacted prefentially with glycated albumin but 
insignificantly when the albumin was not glycated. These antibodies were useful 
then the antibodies raised against antigen which was borohydride reduced 
glycated proteins that have been described by other investigators. Monoclonal and 
polyclonal antibodies generated against the reduced antigen bind to glucitol-lysine 
but does not recognize the unreduced glycated adduct (Curtiss and Witztum, 1983; 
Nakayama et al, 1987; Ohe et al, 1987). Thus, utilization of such antibodies in an 
ELISA or other immunologic recognition assay required modification of the 
sample by borohydride reduction before it could be measured in the assay. The 
monoclonal antibody developed by Cohen and Hud (1989) could be used 
selectively in the assay of glycated albumin in human plasma without subjecting 
the sample to reduction or preparative procedures. 
Taneda and Monnier (1994) raised polyclonal antibodies in New Zealand 
white rabbits against pentosidine coupled to keyhole limpet hemocyanin. The 
antibodies detected by ELISA reacted strongly with free pentosidine but not with 
the structural analogs of pentosodine. They provided a new tool for assessing the 
role of the Advanced Maillard reactions in aging and age-related diseases. A study 
with the antibody by the investigators raised revealed strong pentosidine 
immunoreactivity in neurofibrillary tangles from the brains of patients with 
Alzheimer's disease (Smith et al, 1994). 
Similar attempts were made by Myint et al. (1995) who raised polyclonal 
antibodies specific for the Amadori compound, hexitol lysine coupled with 
various carrier proteins, which were then used to detect glycated proteins by 
immunoblot analysis in various tissues of normal and streptozotocin-induced 
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diabetic rats. It was observed that the affinity purified antibody preferentially 
recognized the glucose adduct in the presence of sodium borohydride as judged on 
ELISA as well as immunoblot analysis. It helped in determining that in diabetic 
conditions kidney, liver, lens, brain and lung proteins are more susceptible to 
glycation than other tissue proteins like muscle or adrenal gland. This was the first 
demonstration of a specific antibody against the Amadori compound being raised 
with a synthetic compound and of the tissue distribution of glycated proteins in 
normal and diabetic conditions. 
In an attempt to clarify the roles of the polyol pathway and its relationship 
to the glycation reactions in diabetic complications, Miyazawa et al. (1998) raised 
antibody against fructated lysine in proteins. The affinity-purified antibody 
specifically recognized proteins incubated with fructose but not with other 
reducing sugars such as glucose, galactose or ribose as judged by immunoblotting 
and ELISA techniques. When soluble proteins prepared from either normal or 
streptozotocin-induced diabetic rat eye lens were analysed by ELISA with this 
antibody, an increase in the reactive components was observed as a function of 
ageing as well as under diabetic conditions. Western blot analysis showed that 
crystallin isolated from rat lens readily reacted with this antibody. 
Similarly, the presence and isolation of increased levels of antibodies 
recognizing AGE-modified and Ns-(carboxymethyl)lysine-modified proteins from 
the sera of streptozotocin-diabetic rats as well as from the plasma of diabetic 
patients was reported by Shibayama et al. (1999). The studies enabled possible 
generation of an autoantibody specific for Ns-(carboxymethyl)lysine that could be 
used as a potential marker for diabetic nephropathy or chronic renal failure. 
Proteins containing AGEs are highly immunogenic and CML is one of the 
major epitopes recognized by anti-AGE antibodies (Reddy et al, 1995; Ikeda et 
al, 1996). So considering the potential use of anti-CML-antibodies as a marker of 
AGEs deposition during diabetes, Vay et al. (2000) investigated the presence of 
anti-CML-antibodies in a large group of diabetic patients from whom samples of 
serum were taken periodically for laboratory analysis. The results obtained on 
analyzing the samples from diabetic patients compared with normoglycaemic 
subjects who donated blood, confirmed that anti-CML-antibodies were 
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statistically significantly increased in diabetic subjects. Using ELISA, titration 
curves and competition experiments they confirmed that in both control and 
diabetic groups anti-CML-reactivity was specific for this (CML) epitope and was 
probably mediated by high affinity IgG. 
Furthermore, immunological strategies for the detection of N(epsilon)-
(carboxymethyl) lysine (CML) are widely applied to demonstrate the contribution 
of CML to the pathogenisis of diabetic complications and atherosclerosis. Thus, in 
order to accurately measure the CML contents of the protein by means of an 
immunochemical method, Koito and his coworkers (2004) prepared CML-specific 
antibodies since conventionally prepared polyclonal anti-CML antibody and 
monoclonal anti-CML antibody (6D12) crossreacted with N(eplison)-
(carboxyethyl)lysine (CEL). To prepare polyclonal CML specific antibody, CML-
keyhole limpet hemocyanin (CML-KLH) were used as an antigen and specific 
antibody was purified using affinity chromatography. Monoclonal antibody 
specific for CML-KLH, followed by successive screening according to CML-BSA 
positive but CEL-BSA negative criteria. Both polyclonal CML-specific antibody 
and CMS-10 significantly reacted with CML-proteins but not with CEL-proteins. 
Thus indicating the ability of these antibodies in recognizing the difference of one 
methyl group between CML and CEL. 
Recently, on similar lines Nagai et al. (2008) prepared specific monoclonal 
antibodies against CML, CEL, N(omega)-(carboxymethyl) arginine (CMA) and S-
(carboxymefhyl)cysteine (CMC). The immunochemical study using anti-CMA 
antibody demonstrated that CMA content increased in a time-dependent manner 
when collagen was incubated with glucose, indicating that immunological 
quantification using the specific antibody is especially useful for measuring an 
acid-liable AGE structure, such as CML. Taken together, the results demonstrated 
that a specific antibody is a powerful tool for analyzing novel biomarkers, 
formation pathways and the efficacy of AGE inhibitors. 
1.7. Objectives of the study 
It is now recognized that uncontrolled diabetes is associated with enhanced 
susceptibility to some infections. Inactivation of the immunoglobulin was the 
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logical explanation and large number of experiments was carried out to examine 
glycation-mediated alteration in structure and biological activity of various 
immunoglobulins. Taking into consideration the long circulating life and the 
remarkable role in immunoprotection, IgG glycation received maximum attention. 
Since sugars are added to immunoglobulins and other proteins during storage and 
pasteurization, study of in vitro glycation is also of considerable interest. 
Antibodies required for in vitro applications like in immunoassays and are raised 
in various animals, a comparative study of susceptibility of IgG isolated from 
various mammalian and an avian source was investigated. While the study 
involved the investigation of effects of various sugars, focus was on fructose 
because of its high reactivity and increasing implications in in vivo glycation 
reactions. Anti-glucose oxidase-IgG raised in rabbits were used for the 
investigation of the effects of glycation on recognition and binding of the enzyme 
antigen. The potential role of antibodies in protection of antigenic protein reported 
from this laboratory (Jabeen et al, 2006 (a) & (b); 2007). A study on the in vitro 
glycation of immunocomplexes of glucose oxidase with anti-glucose oxidase-IgG 
and the fragments derived thereof was also undertaken. Antibodies recognizing 
fructosyl group on the proteins were raised and these were used to study the 
reaction of fructose with protein, when the protein was exposed to the sugar for a 
brief duration or for the entire duration of incubation. 
36 
and 
2.0 Materials 
Chemicals and reagents used in the present studies were obtained from the 
sources as detailed below. Glass distilled water was used in all the experiments. 
B.D.H. Poole, England 
B.D.H., India 
Difco Laboratories Detroit, USA 
E.Merck, India 
Genei Pvt Ltd, Bangalore 
Merck-Schereherdt, Germany 
Sigma Chemical Co, USA 
Qualigen's Research Laboratories 
Bromophenol Blue 
Copper sulphate, hydrochloric acid, 
trichloroacetic acid 
Freund's complete adjuvant, Freund's 
incomplete adjuvant 
Ammonium sulphate, glycine, methanol, 
sodium hydroxide, sodium potassium tartrate 
Molecular weight markers, goat anti-rabbit-
HRP conjugate 
(3-mercaptoethanol 
Nitrocellulose membrane, pepsin, Sepharose 
4B, Comassie brilliant blue R-250, nitroblue 
tetrazolium (NBT),sodium dodecyl sulphate, 
tris (hydroxymethyl amino-methane), 
guanidinum-HCl, trinitrobenzene sulphonic 
acid (TNBS), diethylenetriamine acetic acid 
(DETAPAC), glucose oxidase (GOD). 
Acetic acid, di-sodium hydrogen phosphate, 
glycerol, isopropanol, di-hydrogen sodium 
phosphate, sulphuric acid, sodium chloride, 
sodium bicarbonate, zinc chloride, nickel 
chloride, cobalt chloride, ferric chloride, 
copper chloride, hydrogen peroxide, 
ammonium sulphate, silver nitrate, 
potassium dichromate, Tween-20, di-
potassium hydrogen phosphate, di-hydrogen 
sodium phosphate, ethanol, ethylacetate, 
dinitrophenylhydrazine (DNPH). 
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Sisco Research Laboratories N, N'-methylene bisacrylamide, acrylamide, 
ammonium persulphate, bovine serum 
albumin (BSA), cyanogen bromide, Folin's 
Ciocalteu's phenol reagent, di-ethyl amino 
ethyl (DEAE) Cellulose, ethylene diamine 
tetraacetic acid (EDTA), glucose, fructose, 
ribose, galactose, peroxidase, o-diansidine 
hydrochloride, polyethylene glycol (PEG) 
6000, trichloroacetic acid (TCA). 
Pharmacia Fine Chemicals, Sweden Sepharose fast flow (IDA) 
Hi-Media, India Sodium azide 
Grenier-Labor-Technik, Germany Ninety six welled microtitre plate. 
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3.0. Methods 
3.1. Immunological procedures 
3.1.1. Preparation of the antigen 
For the immunization of rabbits against glucose oxidase were prepared by 
mixing glucose oxidase (600 u.g/0.5 ml 20 mM sodium phosphate buffer, pH 7.2) 
with equal volume of Freund's complete adjuvant. The oil buffer mixture was 
thoroughly emulsified using a 21 gauge syringe. For booster doses, the glucose 
oxidase (300 u.g/0.5 ml 20 mM sodium phosphate buffer, pH 7.2) was mixed and 
emulsified with equal volume of Freund's incomplete adjuvant. Antigen for 
raising antibodies against fructated-BSA was prepared similarly. 
3.1.2. Immunization of rabbits 
Healthy albino rabbits weighing between 2-3 Kg were used for the 
immunizations. The rabbits were bled prior to immunization and the sera obtained 
thus served as controls. Rabbits were injected subcutaneously with 1.0 ml of the 
antigen and rested for fifteen days. Booster doses were subsequently given weekly 
for four weeks. After resting the animal for a week after the last booster, blood 
was collected through posterior ear vein. The blood was allowed to coagulate at 
22°C for three hours, centrifuged to collect antiserum which was then 
decomplemented at 57°C for 30 minutes and stored at -20°C in small aliquots. 
3.1.3. Immunodiffusion 
Immunodiffusion was performed essentially by the method of Ouchterlony 
(1962). One percent molten agarose in normal saline containing 0.2 % sodium 
azide was poured on glass plates and allowed to solidify at room temperature. 
Required number of wells was cut and the plates were stored at 4°C. Thirty to 
thirty five microlitres of suitably diluted antiserum, IgG or reaction mixtures and 
required amount of antigen prepared in normal saline were added in the wells. The 
reaction was allowed to proceed for 12-24 hours in a moist chamber at room 
temperature. The petriplates were immersed in normal saline to remove non-
specific precipitin lines if any. 
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3.1.4. Enzyme linked immunosorbant assay (ELISA) 
3.1.4.1. Buffers and substrates: 
. Tris Buffered Saline (TBS): 20 mM tris, 150 mM sodium chloride, pH 7.4. 
. Tris Buffered Saline Tween-20 (TBS-T): 20 mM tris, 14.3 mM NaCl, 200 mg 
KC1 and 500 ul tween-20 were dissolved in 800 ml distilled water and pH was 
adjusted to 7.4 with 1 N HC1. The volume was made to one litre. 
. Bicarbonate buffer: 50 mM, pU 9.5 contained 0.02% sodium azide as 
preservative. 
. Substrate used is Tetramethylbenzidine/H202 (Commercial preparation diluted 
to 1:4 ratio). 
3.1.4.2. Direct binding ELISA 
Formation of antibodies was measured in the sera of immunized rabbits 
by ELISA (Autsuka, 1979). Ninety six-welled microtitre plates (Greiner Labor-
Technik, France) were coated with 100 ul of antigen at a concentration of 5 mg/ml 
in 0.05 M carbonate bicarbonate buffer, pH 9.6. The plates were incubated for 2 
hours at room temperature and then overnight at 4°C. The antigen-coated wells 
were washed three times with TBS-T buffer in order to remove unbound antigens. 
Unoccupied sites in the wells were blocked with 150 ml of 1.5% (w/v) skimmed 
milk in TBS for three hours at room temperature. The plates were washed with 
TBS-T and serially diluted antiserum (100 u.1/ well) in TBS to be tested was added 
to each well (1:10 -> 1:6, 40000) and incubated for 2 hours at room temperature. 
Bound antibodies were assayed using the commercial secondary antibody-HRP 
conjugate at a 1:3000 dilution. After the usual washing steps the peroxidase 
reaction was initiated by the addition of the substrate tetramethylbenzidine/H202, 
the reaction arrested by the addition of 4.0 N H2S04 and absorbance of each well 
was monitored at 450 nra in and ELISA reader. Each sample was applied in 
duplicate and results were expressed as mean of (Atest - Acontroi). A is the 
absorbance at 410 nm. 
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3.1.4.3. Competition ELISA 
The specificity of the antibodies was determined by competition ELISA 
(Hasan et al, 1991). Varying amount of the soluble antigen (0-20 jig/ ml) were 
mixed with a 100 ul of antiserum or IgG (1:100 dilution). The mixture was 
incubated at room temperature initially for 2 hours and subsequently overnight at 
4°C. The immune complex thus formed was coated on the antigen-coated wells. 
For the remaining steps procedure described for Direct Binding ELISA was 
followed. Percent inhibition was calculated using the formula: 
Percent Inhibition = 1 — . '"" ' e— x 100 
-^-uninhibited 
3.1.4.4. Western blotting 
The specificity of antibodies was also observed by Western blotting 
(Towbin et al, 1979). SDS-PAGE of antigen (7 (j,g in each well) was performed 
using 10% acrylamide gels. Following electrophoresis, the gel was placed in the 
transfer buffer (12 mM Tris, 96 mM glycine and 20% methanol) for 15 minutes 
with gentle shaking. A nitrocellulose membrane (BioRad) was notched to match 
the gel and placed in 100% methanol for 15 seconds, immediately transferred to 
deionized water for 2 minutes and then placed in the transfer buffer again for 3 
minutes. The gel was placed on the nitrocellulose membrane and the transfer was 
allowed to take place at 25 mA overnight in cold room. 
Next day, the membranes were blocked by 5% skimmed milk in phosphate 
buffered saline containing 0.05% Tween 20 (PBS-T) for 2 hours at room 
temperature with gentle shaking. After removal of the blocking buffer, 
appropriately diluted test and control sera were addeJ and binding allowed to 
proceed at room temperature for 2 hours with constant shaking. The membrane 
were rinsed twice and thoroughly washed with IX PBS-T. HRP-conjugated 
secondary antibodies (BioRad) were diluted in PBS-T (1:3000) and the membrane 
was immersed in an enhanced chemiluminescence solution (ECL) on a shaker for 
2 minutes. The membrane was then immediately removed, placed in a plastic 
membrane protector and developed in a dark room with typical exposure periods 
of 30 and 60 seconds using KODAK XR film. 
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3.2. Isolation and purification of Immunoglobulin G 
IgGs from goat, human, rabbit, mouse and buffalo sera were isolated by a 
slight modification of the method of Fahey and Terry (1979). Fifty ml of 
antiserum was mixed with equal volume of 20 mM sodium phosphate buffer, pH 
7.2 and 11.4 gms of solid ammonium sulphate was added. The mixture was stirred 
to dissolve ammonium sulphate and to make it 20% saturated. After 6 hours the 
sample was centrifuged at 2,000 x g for 20 minutes and the supernatant made 40% 
saturated with respect to ammonium sulphate by adding additional 12.3 gms of the 
solid. Precipitation was allowed to proceed for 12 hours at 4°C. The precipitate 
obtained was collected by centrifugation at 2,000 x g for 20 minutes. Most of the 
gamma globulin were present only in the 20-40% pellet which was dissolved in 
minimum volume of 20 mM sodium phosphate buffer, pH 7.2 and extensively 
dialyzed against the same buffer with frequent changes and stored at 4°C. 
Ten grams of DEAE-cellulose was suspended in 0.5 N HC1 for one hour 
and washed in a Buechner funnel with distilled water till the pH of the filterate 
was neutral. The exchanger was then treated with 0.5 N NaOH for 1 hour and 
again washed with distilled water till the pH of the filterate was neutral. DEAE-
cellulose was then resuspended in 20 mM sodium phosphate buffer, pH 7.2 to 
obtain a homogeneous slurry. Fine particles were removed by decantation and the 
slurry was mixed with dialyzed ammonium sulphate fraction and stirred for 2 
hours. The slurry was then centrifuged at 4,000 x g for 10 minutes to settle the 
particles and the supernatant thus obtained containing purified IgG was collected 
and analysed for the protein content. 
3.2.1. Purification of' immunoglobulin^from hen egg yolk (IgY) 
Hen egg yolk IgY fraction was isolated by the procedure of Poison et al. 
(1980). Briefly, the egg yolks were separated from whites and broken by dropping 
through a funnel into a graduated cylinder. An equal volume of buffer (0.01 M 
phosphate, 0.1 M NaCl, pH 7.5 containing 0.01% NaN3) was added and the 
mixture stirred thoroughly. Pulverized PEG 6000 was added by stirring to a 
concentration of 3.5% to facilitate dissolution and the protein precipitate that 
formed was pelleted by centrifugation at 13,000 x g for 10 minutes. The 
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supernatant was decanted and filtered through cheesecloth. Additional PEG was 
added to bring the final concentration of 12% (w/v), the mixture stirred 
thoroughly and centrifuged again at 13,000 x g for 10 minutes. The pellet was 
redissolved to the original yolk volume in 0.01 M phosphate, 0.1 M NaCl, pH 7.5 
and PEG was added to a final concentration of 12% for the second precipitation. 
The supernatant was decanted and the pellet centrifuged twice more to extrude the 
PEG. This IgY pellet was then dissolved in 50 mM Tris, pH 7.9, 0.1 mM EDTA 
containing 0.02% sodium azide. 
The IgY fraction obtained thus was further purified on DEAE-cellulose by 
adsorption at 0.015 M KP04, pH 8.0 and elution with a 0.015-0.3 M KP04> pH 8.0 
gradient (Carroll and Stollar, 1983). 
3.2.2 Preparation and purification ofF(ab) \ dimmers 
The IgG fraction purified from the anti-Glucose oxidase serum was 
digested as described by Nisonoff et al. (1960), with pepsin in order to obtain 
F(ab)'2 fragments. Pepsin (2mg) was dissolved in 1ml of 20 mM sodium acetate 
buffer, pH 4.5. IgG, dialysed against the same buffer was then mixed with the 
enzyme solution to give an enzyme: IgG ratio of 1:100 and the mixture was 
incubated at 37°C for 6 hours. The reaction was terminated by the addition of solid 
tris salt that increased the pH of the reaction mixture to 8.0. The reaction mixture 
was then dialysed against 50 mM tris-HCl, 100 mM NaCl, pH 7.5 buffer. IDA-
Sepharose was washed with 50 mM EDTA and 500 mM NaCl, pH 8.0. Copper 
chloride solution (20 mM) was used to load the matrix with copper ions. The 
matrix was then washed with the operating buffer (50 mM tris-HCl, 100 mM 
NaCl, pH 7.5) and mixed with the dialysed reaction mixture. After incubation for 
1 hour at room temperature, the unbound F(ab)'2 was collected by centrifugation 
at 1000 x g. The fragments were then characterized by SDS-PAGE. 
3.2.3. Preparation and purification ofF(ab)' monomers 
Purified IgG (10 mg/ml) from the antiserum was dialysed against 100 mM 
sodium phosphate buffer, pH 7.0. Cysteine-HCl (1 mg/100 mg IgG), EDTA (0.5 
mg/10 mg) or papain (1 mg/10 mg IgG) were added to the dialyzed IgG and the 
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mixture incubated for 4 hours at 37°C. The digest was rapidly frozen to inhibit 
further digestion and was later dialyzed against 10 mM sodium phosphate buffer, 
pH 8.0 overnight at 4°C. DEAE- Cellulose was regenerated and equilibrated with 
10 mM sodium phosphate buffer pH 8.0. The dialyzed digest was applied or the 
column and a gradient of phosphate buffer was run from 0.01-0.3 M at pH 8.0. 
The first peak to emerge was predominantly that of F(ab)' monomer followed by 
that containing the Fc fragment (Catty and Raykundalia, 1988). The F(ab)' 
fragments were then characterized by SDS-PAGE. 
3.3. In vitro glycation with different sugars 
In order to induce glycation, the protocol used by Miyazawa et al. (1998) 
was adopted with slight modifications. Immunoglobulins purified from various 
mammalian sources and hen eggs, glucose oxidase, intact anti-glucose oxidase-
antibodies, F (ab)^, F (ab)' fragments derived thereof, BSA or ovalbumin were 
subjected to glycation with fructose, glucose, ribose or galactose. The proteins 
concentration was taken as (1 mg/ml) in 20 mM sodium phosphate buffer, pH 7.2 
with respective sugar at the final concentration of 100 mM. Where indicated 25 
mM DETAPAC or EDTA were included. The mixtures were sterilized by 
filtration through a 0.2 urn pore-size nitrocellulose filter and incubated at 37°C for 
8 days under sterile conditions. Samples incubated without sugar similarly served 
as control. Before further analysis each sample was extensively dialyzed against 
the buffer in order to remove excess of sugars. 
3.4. Raising of anti-(fructosyI group)-antibodies in rabbits 
3.4.1. Immobilization offructated-ovalbumin on Sepharose 
Sepharose 4B was activated as described by Porath et al, (1967). One 
gram Sepharose was washed thoroughly with distilled water in a sintered glass 
funnel. The gel was sucked dry and suspended in 2.0 ml of distilled water and 1.0 
ml of 2.0 M sodium bicarbonate (Na2CC>3). The slurry was stirred thoroughly at 
room temperature by placing it on a magnetic stirrer. Then 0.2 gm of cynogen 
bromide dissolved in 0.2 ml of acetonitrile was added to the beaker containing 
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Sepharose gel and mixed thoroughly at 4°C for 15 minutes. The whole mass was 
then transferred immediately to a glass sintered funnel and washed extensively 
with 0.1 M bicarbonate buffer, pH 8.5, distilled water and then with phosphate 
buffer. After thorough washings, the activated Sepharose was dried and suspended 
in 0.1 M sodium bicarbonate buffer, pH 8.5. 
Fructated-ovalbumin (6 mg/ml) was added to the CNBr-activated 
Sepharose in 0.1 M sodium bicarbonate buffer, pH 8.5. The suspension was 
constantly stirred at 4°C for 24 hours. The unbound protein was separated by 
centrifugation and the protein bound matrix was washed thoroughly with 0.1 M 
sodium bicarbonate buffer, pH 8.5 containing 1.0 M NaCl. After washings, the 
protein bound matrix was treated with 98% ethanolamine to block the remaining 
activated groups on the matrix. Later the matrix was washed finally with 20 mM 
sodium phosphate buffer, pH 7.2. The bound protein was calculated by subtracting 
the unbound protein in the washings from that added. The preparation obtained 
contained 5 mg fructated-ovalbumin per ml of gel. 
3.4.2. Purification of specific anti-(fructosyl group)-antibodies from the serum 
of immunized rabbits 
Antibodies raised in rabbits were purified by affinity chromatography 
employing fructated-ovalbumin affinity column. Two ml of serum obtained from 
rabbits immunized with fructated-BSA was applied to the Sepharose column. 
Column exit was closed and the antiserum was allowed to bind to matrix at room 
temperature for 30-40 minutes. The column was washed thoroughly with 20 mM 
phosphate buffered saline, pH 7.2 to remove any unbound protein. Bound 
antibodies were eluted with 0.1 M glycine/HCl buffer, pH 3.0 and the eluate was 
immediately neutralized with predetermined volume of 1 M Tris Buffer, pH 8.8. 
Purity of IgG was determined by SDS-PAGE. 
3.5. Colorimetric Analysis 
3.5.1. Determination of protein concentration 
Protein was estimated by the method of Lowry et al. (1951). Aliquots of 
protein solution were taken in a set of tubes and final volume made up to 1 ml 
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with 0.01 M sodium phosphate buffer, pH 8.0. Five ml of alkaline copper reagent 
(containing one part of 0.5% (w/v) copper sulphate, 1% (w/v) sodium potassium 
tartarte and fifty parts of 2% (w/v) sodium hydroxide) was added, followed after 
10 minutes of incubation at room temperature with 0.5 ml of 1.0 N Folin-
Ciocalteu's phenol reagent. The tubes were instantly vortexed. The colour 
developed was read at 660 nm after 30 minutes against the reagent blank. A 
standard curve was prepared using BSA as standard. 
3.5.2. Amino group estimation 
The amino groups of protein were determined by the method of Habeeb 
(1966) with slight modification. Suitable aliquots of sample were dissolved in 1.0 
ml of 0.1 M sodium tetraborate buffer, pH 9.3, 25 ul of 0.3 M TNBS added and 
the tubes agitated instantly to ensure complete mixing and allowed to stand for 30 
minutes at room temperature. Absorbance of the yellow colour developed was 
recorded at 420 nm against a reagent blank. Glycine was used as a standard amino 
acid. 
3.5.3. Determination of protein bound carbonyl groups 
Protein -bound carbonyl groups were estimated according to the protocol 
of Levine et al, (1990); briefly 200 ui aliquot (containing 0.1 mg of protein) was 
mixed with 400 JJ.1 of 7 mM DNPH in 2 M HC1. The mixtures were run in 
duplicate and the control protein samples were devoid of DNPH. After incubation 
for 1 hour at room temperature the DNPH-hydrazones were precipitated by adding 
500 u.1 of TCA (4% w/v) and centrifuged for 5 mins at 14,000 x g and the pellet 
was dispersed in ethanol-ethylacetate (1:1 v/v), in order to remove unreacted 
DNPH and centrifuged. After 4 such washes, the pellet was resuspended in 0.6 ml 
of 6 M guanidinum HC1 solution in 20 mM phosphate buffer, already adjusting to 
pH 2.3 with trifluoroacetic acid. The hydrazones wee dissolved completely only 
by freezing overnight at -20°C and thawing. From the solution, 200 ul aliquot was 
taken into a microplate and read at 379 nm by a microplate reader. The results 
were expressed as the number of nanomoles of carbonyl per mg of sample protein 
using a 8379 nm = 22000 M ' W [21]. 
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3.5.4. Assay of glucose oxidase 
Activity profile of control glucose oxidase and that after treatment with 
sugar in the presence and absence of antibody or its fragments was assayed by the 
procedure given by Hatton and Regoeczi (1976); glucose was prepared as 150 
raM solution. Peroxidase and o-diansidine hydrochloride were added to 50 raM 
sodium phosphate buffer, pH 6.1 to give a final concentration of 0.01%. One ml of 
150 mM glucose was added to 1.8 ml of freshly prepared peroxidase o-diansidine 
hydrochloride reagent. The tubes were incubated at 37°C for 2 minutes and then 
0.2 ml (2.5 Lxg) GOD added. After incubation at 37°C for 10 minutes 4.5 M 
sulphuric acid was added to stop the reaction and the pink colour obtained was 
read at 550 nm. 
One unit of glucose oxidase is the amount that oxidizes 1 micromole of 
glucose to gluconic acid and hydrogen peroxide per minute at 37°C, pH 6.1. 
Percent remaining activity of glucose oxidase was calculated as follows; 
Percent remaining activity = 100 - X 
X = Control-Treated
 x JQQ 
Control 
3.6. Spectral Analysis 
3.6.1. UV absorption spectroscopy 
The UV absorption spectroscopy of native and sugar treated samples were 
obtained by measuring the absorption between 200 - 400 nm in a Shimadzu 
spectrophotometer using a cuvette of 1 cm pathlength. Three hundred micrograms 
of native and treated samples in a total volume of 1 ml was taken for spectral 
analysis. 
3.6.2. Flourescence spectroscopy 
Native and sugar treated samples (100 \igl ml) were analysed by 
measuring intrinsic fluorescence at 25±0.2°C in a Hitachi F2000 spectrofluorometer 
(Tokyo, Japan). The samples were excited at 285 nm and emission range was 
taken at 310-460 nm. Fluorescence measurements were also made at 370 nm 
excitation and an emission range of 400-500 nm. Appropriate controls containing 
the substances used for the treatment were run and corrections were made 
wherever necessary. 
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3.7. Slab gel electrophoresis 
3.7.1. Poly aery lamide gel electroph ores is (PA GE) 
Electrophoresis was performed essentially according to the method of 
Laemmli (1970) using the slab gel apparatus manufactured by Biotech, India. A 
stock solution of 30% acrylamide containing 0.8% bisacrylamide was mixed in 
appropriate proportion to give the desired percentage of gel. It was then poured 
into the mould formed by two glass plates (8.5 x 10 cm) separated by 1.5 mm 
thick spacers. Bubbles and leaks were avoided. A comb providing a template for 
seven wells was quickly inserted into the gel film and polymerization allowed to 
occur. After 15-20 minutes, the comb was removed and the wells were cleaned, 
overlaid with running buffer. Samples containing 15-35 \ig protein mixed with 
equal volume of sample buffer (containing 10% (v/v) glycerol, 0.06 M tris HC1, 
pH 6.8 and traces of bromophenol blue as tracking dye) were applied to the wells. 
Electrophoresis was performed at 100 V in the electrophoresis buffer containing 
0.025 M tris and 0.2 glycine until the tracking dye reached the bottom of the gel. 
3.7.2. Sodium dodecyl sulphate poly aery lamide gel electrophoresis 
(SDS-PAGE) 
Sodium dodecyl sulphate (SDS) PAGE was performed by the tris-glycine 
system of Laemmli (1970) using slab gel electrophoresis apparatus, manufactured 
by Biotech, India. Concentrated stock solution of 30% acrylamide containing 
0.8% bisacrylamide, 1.0 M tris (pH 6.8 and 8.8) and 10%) SDS were prepared and 
mixed in appropriate proportion to give the final required percentage. It was 
poured in the mould formed by two glass plates (8.5 x 10 cm) separated by 1.5 
mm thick spacers avoiding leaks and bubbles. A comb providing a template for 
seven wells was quickly inserted into the gel before the polymerization began. 
•The comb was removed once the polymerization was complete and wells were 
overlaid with the running buffer. Protein samples were prepared in the sample 
buffer containing 1% (w/v) SDS, 10% (v/v) glycerol, 0.0625 M tris HC1, pH 6.8 
and traces of bromophenol blue as tracking dye along with 5% (3-mercaptoethanol. 
The samples were boiled at 100°C for five minutes. Electrophoresis was 
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performed in electrophoresis buffer containing 0.025 M tris and 0.2 M glycine at 
100 v till the tracking dye reached the bottom of the gel. 
3.8. Staining procedures 
After the electrophoresis was complete the gels were removed and the 
protein bands were visualized by staining. 
3.8.1. Coomassie brilliant blue staining 
Protein bands were detected by staining with 0.1% coomassie brilliant blue 
R-250 in 40% isopropanol and 10% acetic acid. The staining was carried out with 
10% glacial acetic acid. 
3.8.2. Silver nitrate staining 
The procedure described by Merril et al. (1982) was followed. After 
electrophoresis the protein bands were fixed by rapidly immersing in a mixture of 
40% (v/v) methanol and 10% (v/v) acetic acid for one hour with constant shaking. 
The gel was washed with 10% methanol and 5% (v/v) acetic acid twice, each time 
for 15 minutes to allow the gel to swell to normal size. This was followed by 
incubation in 3.4 mM potassium dichromate solution containing 3.2 mM nitric 
acid for 15 minutes and then thoroughly washed with distilled water. The washed 
gel was then immersed in 12 mM silver nitrate solution for 20 minutes and the 
again washed with distilled water and transferred to 280 mM solution of sodium 
carbonate containing 0.5% formaldehyde to make the gel alkaline. The reaction 
was stopped after 10 minutes by transferring the gel to 3% acetic acid solution for 
5 minutes. The gels were washed 4 to 5 times with distilled water and finally 
stored in distilled water. 
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Purification of antibodies from various mammalian and 
avian sources and investigation of the effect of in vitro 
glycation with fructose on their structure and immune 
reactivity. 
4.0. Results and Discussion 
4.1. Purification of immunoglobulin from various mammalian sources and an 
avian source 
The procedure of Fahey and Terry (1979) was followed for the purification 
of IgGs from the sera of goat, human, rabbit, buffalo and mouse, while IgY was 
purified from hen egg yolk (Poison et al, 1980). Purification of IgG was followed 
by SDS-PAGE in the presence of the thiol reductant |3-mercaptoethanol. All the 
immunoglobulins appeared homogeneous and migrated characterstically as one 
large molecular weight and a small molecular weight band, suggesting 
homogeneity (Figure 12 a). The molecular weight of the polypeptides of IgG was 
calculated as per the procedure of Weber and Osborn (1969) by plotting the 
mobility of marker protein vs the logarithim of their molecular weights (Figure 12 
b). The position of the migration of large and small polypeptides corresponded to 
apparent molecular mass of 48.0 kDa and 25.0 kDa. Staining intensity especially, 
that of the small molecular weight peptide, corresponding to the light chain 
polypeptide indicated wide variation and that of rabbit appear to have migrated 
somewhat slowly. 
4.2. Purification of anti-glucose oxidase-IgG 
Aspergillus niger glucose oxidase used for the study was highly 
immunogenic and rabbits challenged with the enzyme responded by producing 
precipitating antibodies. Figure 13 shows clear precipitin lines indicating the 
formation of anti-glucose oxidase antibodies. 
Immunogenicity of glucose oxidase was further confirmed by ELISA 
(Figure 14). Preimmune and immune sera from 1:10 to 1: 6,40000 dilution were 
coated in the wells for titre determination. After blocking of the wells with 
skimmed milk they were again incubated with the peroxidase linked secondary 
antibody. The plates were then developed for the peroxidase activity. The 
immunized rabbit serum samples exhibited a high titre (upto 39,323) in ELISA. 
Figure 15 illustrate specificity of anti-glucose oxidase-antibodies to the 
enzyme. Results point to a higher reactivity of both antisera and 
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Figure 12(a): SDS-PAGE of purified IgG from mammalian sources and an 
avian source. 
Lanes 1, 2, 3, 4, 5 and 6 contain goat IgG, human IgG, rabbit 
IgG, buffalo IgG, hen egg yolk IgY and mouse IgG respectively. 
Lane 7 contains the molecular mass markers (20 ug). The 
samples were subjected to SDS-PAGE in presence of 0-
mercaptoethanol. The gels were silver stained for visualization of 
the protein bands. Twelve to fifteen micrograms of IgG samples 
were loaded in respective lane. 
Figure 12(b): Molecular weight determination by Weber and Osborn 
procedure. 
The relative mobility of the standard marker proteins from SDS 
gel was plotted against logarithm of molecular weight using least 
square analysis. Arrows indicate the positions of the large and 
small molecular weight peptides from the DEAE fraction. 
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Figure 13: Ouchterlony Double Immunodiffusion of glucose oxidase against 
anti- glucose oxidase-antiserum. 
Rabbits were immunized with glucose oxidase and the antiserum 
obtained was fractionated to purify anti-enzyme antibodies. 
Immunodiffusion was performed in 1% agarose gel prepared in 
normal saline. The central well contained 15 ug of glucose oxidase, 
while outer wells contained 30 ul of antiserum. 
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Figure 14: Cross Reactivity of the anti-glucose oxidase- antibodies with the 
enzyme. 
Glucose oxidase (0.5 u,g/well) was coated on the ELISA plate and 
were processed for the Direct Binding ELISA steps as described in 
the text. Various dilutions of the preimmune sera (••••••^ ••••) and glucose 
oxidase specific antisera (—•—) were added to the plate. Finally the 
plate was developed with the colouring agent and absorbance of the 
coloured complex was measured at 410 nm. 
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Figure 15: Specificity of the anti-glucose oxidase-antibodies with the enzyme. 
The antigenic specificity of the antibodies was determined by 
competitive ELISA. Glucose oxidase (0-20 u.g/ml) was mixed with 100 
ul of preimmune sera ( ^ ), antisera ( B ) or IgG (1:100 dilution) 
(—A—) added to the glucose oxidase-coated wells instead of antisera. 
The remaining steps were the same as in Direct Binding ELISA. 
Finally the plate was developed with the colouring agent and 
absorbance of the coloured complex was measured at 410 nm. 
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purified antibodies towards antigenic glucose oxidase. The percent binding of the 
enzyme from the solution to the antibodies and antisera was 80% and 70% 
respectively at its maximum concentration. Thus indicating presence as well as 
purification of antibodies with high specificity towards glucose oxidase (Mansoor 
et al, 2005). 
For the purification of anti-glucose oxidase-IgG from the sera of 
immunized animals, the procedure of Fahey and Terry (1979) was followed. 
Purification was followed by polyacrylamide gel electrophoresis both in the 
absence and presence of SDS. Native PAGE of whole antiserum and ammonium 
sulphate fractions showed bands corresponding to IgG. and several polypeptides 
but the DEAE-cellulose purified preparation gave a single band of IgG (Figure 16 
a). In order to determine the molecular weight of IgG, SDS-PAGE (reducing) of 
the samples were run along with molecular weight markers (Figure 16 b). The 
anti-glucose oxidase-IgG appeared homogenous and migrated characteristically as 
one large molecular weight and a small molecular weight band. The position of 
the migration of large and small polypeptides corresponded to apparent molecular 
mass of 48.0 kDa and 25.0 kDa. 
4.3. In vitro glycation of the immunoglobulin with fructose 
4.3.1. Electrophoretic behaviour 
Incubation of the immunoglobulins purified from various mammalian and 
an avian source with fructose resulted in a time-dependent decrease in the 
intensity of the bands corresponding both to the heavy and light chains (Figure 
17). Glycation of proteins has been shown to result in protein degradation and/or 
crosslinking (Singh et al, 2001; Rosea et al, 2005) and the observed decrease in 
the intensity of the bands apparently results from such effects. The fructose-
induced loss of band intensity appeared most prominent in case of IgY followed 
by buffalo, mouse, rabbit, human and goat IgG. While appearance of small 
peptides could not be noticed, presence of material that failed to enter into the gels 
and could be silver stained was detectable, particularly in the lanes containing IgY 
and rabbit IgG, suggesting the formation of aggregates, too large to enter the gel 
-iw 
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Figure 16: PAGE of anti-glucose oxidase-IgG during various stages of 
purification under nonreducing (a) and reducing (b) conditions. 
(a) Lanes 1, 2 and 3 contain fraction from DEAE-cellulose (12 ug), 20-
40% ammonium sulphate fraction (15 ug) and antiserum (15 (ig) 
respectively. The samples were subjected to electrophoresis on 7.5% 
gel under non-reducing conditions. The gel was silver stained for 
visualization of the protein bands. 
(b) Lanes 1, 2, 3 and 4 contain molecular mass markers (20 ug), fraction 
from DEAE-cellulose (12 ug), 20-40% ammonium sulphate fraction 
(15 ug) and antiserum (15 ug) respectively. The samples were 
subjected to SDS-PAGE in presence of |>mercaptoethanol. The gel 
was silver stained for visualization of the protein bands. 
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Figure 17: Effect of incubation on IgG derived from s>ira of various animals 
incubated with fructose. 
The IgG isolated from goat (12 (ig) (A), human (12 ug) (B), rabbit 
(15 ug) (C), mouse (15 |ig) (D), buffalo (12 ug) (E) and hen egg yolk 
IgY (15 ug) (F) were incubated with 100 mM fructose. Lane 1 
contains immunoglobulin incubated without fructose for 8 days. 
Lane 2-6 contains sample incubated with fructose for 1, 3, 5, 6 and 8 
days respectively. The samples were subjected to SDS-PAGE in 
presence of p-mercaptoethanol. The gels were silver stained for 
visualization of protein bands. 
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pores. Fragmentation of the immunoglobulins to very small peptides may however 
go undetected in the gels. Gel Alteration performed in a preliminary study 
however suggested that only less than 10 percent of protein can be detected in the 
void volume of a Sephacryl S-200 column after incubation of buffalo IgG with 
fructose. This suggests the formation of aggregates may not be the principal cause 
of the observed decrease in intensity of the immunoglobulin band. 
In all the immunoglobulin samples investigated, the intensity of the band 
corresponding to the large polypeptide decreased more rapidly as compared to that 
of the small molecular weight counterpart. In fact incubation for eight days with 
fructose resulted in near complete disappearance of the large molecular weight 
band in case of the IgY, mouse and rabbit IgG, although significant staining in the 
region of low molecular weight band was still evident (Figure 17). The bands may 
disappear from the position if protein undergoes cross-linking and forms 
aggregates too large to enter the gel (Syrovy, 1992). Selective loss of the heavy 
chain also however suggests proteolysis rathe/ than aggregation in the fructose-
treated immunoglobulins. One possible reason is the selective degradation of the 
polypeptide by reactive oxygen species (ROS) especially, the hydroxyl radicals 
produced during glycation reaction (Baynes and Thorpe, 1997). Hydroxyl radicals 
generated during Fenton reaction have been shown to cleave peptide bonds 
(Ookav/ara etal., 1992). 
In order to detect the possible role of metal ions in the fructose-induced 
alterations in the immunoglobulins, effect of inclusion of the chelating agents 
DETAPAC and EDTA was investigated. Figure 18 shows SDS-PAGE analysis of 
immunoglobulin G from goat, human, rabbit, mouse, buffalo and hen egg yolk 
IgY samples incubated with fructose in the presence of EDTA and DETAPAC. 
Both EDTA and DETAPAC were effective in restricting the alteration in the 
migration profile of the immunoglobulin bands. The polypeptide bands in the 
samples incubated with fructose in presence of the chelators were of comparable 
intensity with those of controls and the protective effect of the chelators was 
found to be uniform on IgGs from all the sources. DETAPAC was more effective 
than EDTA in this regard. Earlier studies have shown that DETAPAC and EDTA 
restrict glucose-induced fragmentation of protein and autoxidation in the presence 
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Figure 18: SDS-PAGE of Goat IgG (A), Human IgG (B), Rabbit IgG (C), 
Mouse IgG (D), Buffalo IgG (E) and Hen egg yolk IgY (F) 
incubated with fructose in the absence or presence of metal 
chelators (DETAPAC and EDTA). 
Lane 1 contains immunoglobulin incubated without fructose. Lanes 2 
contains sample incubated with 100 mM fructose. Lane 3 & 4 
contains sample incubated with fructose in the presence of 25 mM 
DETAPAC or EDTA respectively. All the samples were incubated 
for 8 days. The samples were subjected to SDS-PAGE in presence of 
P-mercaptoethanol. The gels were silver stained for visualization of 
protein bands. The amount of sample loaded in each case is as 
follows, goat (12 ng), human (12 ug), rabbit (15 ug), mouse (15 ug), 
buffalo (12 ug) and hen egg yolk (15 ug). 
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as well as in the absence of added metal ions, suggesting the role of trace metal 
ions present in the buffers in the autoxidation of sugars and transformation of 
Maillard products to AGE (Wolff et al, 1984; Wolff and Dean, 1987; Hunt et al, 
1988). Apparently the trace metal ions also play an important role in the induction 
of alterations observed in case of immunoglobulins incubated with fructose in this 
study. Earlier studies have shown DETAPAC and EDTA both in the presence and 
absence of added metal ions lead to virtual abolition of protein fragmentation 
(Hunt et al, 1988). Glucose autoxidizes in vitro and generates H2O2 and 
ketoaldehydes especially in the presence of proteins and metal chelators bring 
about inhibition of such monosaccharide reaction with the proteins (Wolff and 
Dean, 1987). 
4.3.2. Spectroscopic studies 
The fructose-induced alterations in immunoglobulins derived from 
various animals were further examined with respect to their chromophoric and 
fluorophoric properties. The UV spectra of all the IgG samples incubated with 
fructose showed marked increase in absorbance at 280 nm, as compared to those 
not exposed to the sugar. The magnitude of hyperchromicity however varied 
remarkably among the immunoglobulins derived from various animals. Human 
IgG was incubated with fructose showed maximum hyperchromicity followed by 
those of mouse, buffalo, rabbit IgG, hen IgY and goat IgG (Figure 19). The order 
of fructose-induced hyperchromicity shown by the immunoglobulins was different 
from that of alterations revealed by SDS-PAGE. The fructose-induced loss of 
band intensity appeared most prominent in case of IgY followed by buffalo, 
mouse, rabbit, human and goat IgG (Figure 17). Goat IgG appeared most resistant 
and exhibited minimum alterations both in hyperchromicity and electrophoretic 
behaviour. The large variations observed in the fructose-induced hyperchromicity 
among various immunoglobulins are suggestive of differences in structure and in 
turn to conformational alterations and/or fragmentation. Hyperchromicity in the 
UV region can be attributed to the exposure of the chromophoric aromatic 
residues due to unfolding of the molecules and/or fragmentation of the 
immunoglobulins (Traverso et al, 1997). 
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Figure 19: Hyperchromicity of immunoglobulin incubated with fructose. 
Immunoglobulins were dialysed and equivalent quantities of protein 
were taken for ultraviolet spectroscopy. The immunoglobulin samples 
were incubated with 100 mM fructose in the absence ( 0 ) or presence 
of 25 mM DETAPAC (@) or EDTA (DD) in 20 mM phosphate buffer 
pH 7.2 for 8 days. All values are mean ± S.D for three experiments 
performed in duplicate. 
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Quenching of tryptophan fluorescence (285 nm exc. / 335 nm em.) of the 
immunoglobulins was also measured as an additional index of alteration in the 
structure/conformation (Jukus et al, 1998). Incubation with fructose resulted in 
quenching of tryptophan fluorescence in the immunoglobulins derived from goat, 
human, rabbit, mouse, buffalo and hen egg yolk (Figure 20), but the magnitude of 
quenching also varied very markedly; maximum quenching was observed in case 
of buffalo IgG and the quenching minimum in case of hen egg yolk IgY. 
Fluorescence spectra showed a red shift of emission peak by 5 nm, in case of hen 
IgY incubated with fructose while the shift was of 10 nm with mouse IgG treated 
with the sugar. Loss of tryptophan fluorescence is ascribed to the destruction of 
tryptophan and/or modification of the tryptophan microenvironment (Shaklai et 
al, 1984; Daviess al, 1987). 
Increase in new fluorescence, measursd by excitation at 370 nm and 
emission at 440 nm, is characteristic of the several glycated proteins and used as a 
measure of protein glycation (Dolhofer-Bliesner and Gerbitz, 1990). A marked 
increase in the new fluorescence was observed when the IgG from various animals 
and hen IgY were incubated with fructose (Figure 21). The order of increase in 
new fluorescence shown by the immunoglobulins was comparable to the order of 
the alterations observed in SDS-PAGE. Maximum increase in the new 
fluorescence was observed in case of hen IgY followed by buffalo, rabbit, mouse 
and human IgG, while increase was minimum in case of goat IgG. This further 
suggests that the goat IgG is most recalcitrant to incubation with fructose. The 
extent of variation in the enhancement of new fluorescence among the 
immunoglobulins was however less marked as compared to those observed with 
fluorescence quenching and absorbance at 280 nm. The new fluorescence is 
ascribed to the formation of various fluorophores, whose relative contribution may 
vary broadly depending on the site, extent of glycation and accompanying 
autoxidation (Huggins et al, 1993). 
In the immunoglobulin samples containing DETAPAC and EDTA, 
hyperchromicity, tryptophan quenching and development of new fluorescence 
were remarkably restricted. The magnitude of protection offered by the 
chelators varied between 65-75%. Also good agreement was observed in the 
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Figure 20: Tryptophan fluorescence of immunoglobulin incubated with 
fructose. 
Immunoglobulins were dialysed and equivalent quantities of protein 
were taken for tryptophan fluorescence. The immunoglobulin 
samples were incubated with 100 mM fructose in the absence (03) 
or presence of 25 mM DETAPAC ( g ) or EDTA (HD) in 20 mM 
phosphate buffer pH 7.2 for 8 days. All values are mean±S.D for 
three experiments performed in duplicate. Fluorescence values of 
untreated IgG were taken as 100 to calculate the percent 
fluorescence of various samples. 
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Figure 21: New fluorescence of immunoglobulin incubated with fructose. 
Immunoglobulins were dialysed and equivalent quantities of protein 
were taken for new fluorescence. The immunoglobulin samples were 
incubated with 100 mM fructose in the absence (Qj3) or presence of 25 
mM DETAPAC (@) or EDTA ( H ) in 20 mM phosphate buffer pH 
7.2 for 8 days. All values are mean±S.D for three experiments 
performed in duplicate. 
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effectiveness of these chelators both in, spectroscopic analysis and eletrophoresis. 
DETAPAC and EDTA are believed to chelate trace metal ions thus inhibiting the 
formation of reactive carbonyl species which act as important precursors of AGEs 
(Thornalley et al, 1999; Peyroux and Sternberg, 2006). 
4.3.3. Chemical Modifications 
Figure 22 shows that the amino groups of various native immunoglobulins 
accessible to reaction with TNBS under the conditions used. Goat IgG revealed 
the minimum number of exposed amino groups per molecule while they were 
maximum in the hen IgY. However, treatment with fructose resulted in steep 
decrease in amino group number in all the immunoglobulins. Goat IgG with 
minimum number of exposed aminogroups were most recalcitrant among the 
immunoglobulins investigated as evident from SDS-PAGE, hyperchromicity in 
the UV and development of new fluorescence, while hen IgY were found to be 
most susceptible. This is not unexpected since glycation of proteins begins with 
the reaction of sugars mainly with the amino groups and supports the earlier 
observation of Lapolla et al (2000; 2001), that exposed amino, groups may play 
an important role in determining the susceptibility to glycation by the sugars. 
MALDI spectra of digested IgG carried out by Lapolla et al, (2001; 2004) 
showed that twenty glucose molecules condense onto one Fab" portion and ten 
onto the Fc' portion of IgG. Moreover reduction in the total amino group content 
on glycation is expected since monosaccharides bind to free amino groups. The 
glyoxidation products of sugars like a-ketoacids on the other hand, react 
preferentially with the guanidine group of arginine (Yankeelov, 1972). The 
number of reactive amino groups of a protein alone may not therefore determine 
the magnitude of alterations that accompany glycation. Among the side chain 
amino groups of proteins, those with low pKa and more importantly those that 
facilitate low acid-base catalysis are the ones that are preferentially modified 
during glycation (Morin et al, 1987). 
Glycated immunoglobulins were further analysed for their carbonyl 
content by reaction with DNPH. Figure 23 shows production of carbonyl groups 
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Figure 22: Effect of incubation with fructose on the amino group of 
immunoglobulins derived from various animals. 
Immunoglobulins were incubated without fructose Q ) and with 100 
mM fructose ( g ) in 20 mM phosphate buffer pH 7.2 for 8 days. IgGs 
were dialysed and equivalent quantities of protein were taken for 
analysis. All values were mean±S.D. for three experiments 
performed in duplicate. 
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Figure 23: Effect of incubation with fructose on the carbonyl group content 
of immunoglobulins derived from various animals. 
Immunoglobulins were incubated without fructose O ) a nd with 100 
mM fructose (§|) in 20 mM phosphate buffer pH 7.2 for 8 days. IgGs 
were dialysed and equivalent quantities of protein were taken for 
analysis. All values were mean ± S.D. for three experiments 
performed in duplicate. 
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in the samples treated with fructose for eight days. Buffalo IgG and hen egg yolk 
IgY contained maximum carbonyl groups while there were minimum in case of 
the goat IgG. These results substantiate observations made earlier that goat IgG 
are most resistant to glycation. Samples incubated without fructose showed 
negligible carbonyl group content. Reaction with DNPH is a standard method for 
detecting carbonyl groups, and can be used to follow changes on protein glycation 
(Liggins and Furth, 1997). The carbonyls detected under the conditions are clearly 
the result of glycooxidation or sugar autoxidation (Marcon et al, 2003), since 
there is little DNPH-reactivity in the proteins incubated in buffer alone. Earlier 
studies have also shown that glycation generates carbonyls, probably by damaging 
the protein structure through oxidative mechanisms (Fu et al, 1992). 
4.3.4. Effect of incubation with fructose on the binding of anti-glucose oxidase 
IgG to glucose oxidase 
The IgG isolated from the sera of rabbits immunized with glucose oxidase 
also facilitated investigations on the effect of glycation on the ability of the 
antibodies to bind to the enzyme-antigen. The anti-glucose oxidase-IgG showed a 
remarkable decrease in the ability to bind to glucose oxidase on incubation with 
fructose as revealed by immunodiffusion. The antigen was loaded in the central 
well of each plate, while the samples incubated with or in the absence of fructose 
were added to the peripheral wells. As shown in Figure 24, sharp precipitin lines 
were obtained in plate containing antiglucose oxidase IgG not incubated with 
fructose. Antiglucose oxidase IgG incubated with fructose even for one day 
resulted in diffused precipitin lines and when the incubation was extended to three 
days, no precipitin lines were observed. 
Direct Binding ELISA in Figure 25 shows that increase in the time of 
incubation with fructose lead to decrease in binding to glucose oxidase. The 
decrease appeared small till the third day but increased remarkably after five days. 
. Since IgG derived from various animals exhibit remarkable structural similarity, 
minor differences in structure may contribute significantly towards the alterations 
resulting from glycation by sugars. It is likely that specific location of the 
susceptible aminoacid side chains in or close to the antigen binding sites may 
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Figure 24: Ouchterlony Double Immunodiffusion of fructose-treated rabbit 
IgG against its antigen. 
Immunodiffusion was performed in 1% agarose gel prepared in 
normal saline. The central wells contained 40 ul of 1 mg/ml antigen 
(Glucose oxidase) while same amount of the control sample (A) and 
anti-glucose oxidase-IgG incubated with 100 raM fructose in the 
absence (B and C) or presence of 25 mM DETAPAC (D and E) or 
EDTA (F and G) for 1 and 3 days were added to the outer wells of 
different plates respectively. 
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Figure 25: Effect of incubation with fructose on ELISA analysis of anti-
glucose oxidase-antibodies. 
ELISA analysis of anti-glucose oxidase-IgG incubated with buffer 
(c) or 100 mM fructose in the absence ( 0 ) or presence of 25 mM 
DETAPAC ( n ) or EDTA (H) was performed as described in 
methods. All the values are mean±S.D. for three experiments 
performed in duplicate. 
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determine the sensitivity to glycation-induced loss in ability to bind to 
antigen. 
Sasaki et al. (1993) and Kennedy et al. (1994) reported glycation induced loss 
of ability of mouse monoclonal antibodies to bind to the antigen. Our studies 
carried out using the anti-GOD antibodies raised in rabbits support their 
observations. As evident from Figures 17, 19, 20 and 21 remarkable similarities 
exist in the response of the mouse and rabbit immunoglobulins to the alterations 
induced by fructose indicating their structural similarity. It is however not unlikely 
that different antibodies raised in the same animal may differ in their sensitivity to 
glycation, depending upon the reactivity of amino acids in and around the 
antigen/epitope binding sites. 
The anti-glucose oxidase-IgG incubated with fructose in the presence of 
metal chelators (DETAPAC and EDTA) showed the formation of appreciable 
precipitin lines on immunodiffusion and significant binding to glucose oxidase as 
revealed by ELISA. These findings substantiate the protective effect of the 
chelating agents observed against alterations in electrophoretic behaviour, and the 
role of trace metal ions in protein glycation and autoxidation (Hunt et al, 1988; 
Wolff ef al, 1984). 
4.4. Conclusion and implications of the study 
Immunoglobulins are major components of mammalian sera and 
considerable evidence suggests that they undergo in vivo glycation (Danze et al, 
1987; Hennessey et al, 1991). Glucose is the principal sugar to which the 
circulating immunoglobulins are exposed to and the concentration of the sugar 
may increase remarkably in diabetics. While serum fructose levels are not 
unusually very high, excessive consumption of the sugar may cause considerable 
damage to the serum proteins because of the high reactivity of the sugar (Bunn 
and Higgins, 1981). Fructose was selected as a model sugar also because of its 
ability to cause glycation more rapidly than glucose in ritro. Also the in vitro 
sugar induced alterations in immunoglobulins are of interest since these are added 
during pasteurization, to prevent precipitation during storage and facilitate freeze-
drying (Vrdoljak et al, 2004). This study suggests that immunoglobulins derived 
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from various animals differ remarkably in their susceptibility to fructose-induced 
fragmentation/crosslinking, hyperchromicity, tryptophan fluorescence quenching 
and development of new fluorescence. Goat IgG appeared most recalcitrant and 
hen egg yolk IgY most susceptible by majority but not all parameters. Metal ions 
appear to play a remarkable role in the process. The number of exposed amino 
groups also appear to play an important role in the susceptibility of the 
immunoglobulins to glycation (Lapolla et al, 2001; 2004). Goat IgG contain 
minimum number of exposed amino groups and was most resistant while hen IgY 
which appear to be most susceptible, contained maximum number of amino 
groups. However among the immunoglobulins containing intermediate range of 
exposed amino groups the glycation-mediated damage did not occur strictly 
according to the order. 
Anti-glucose oxidase-IgG rapidly lost the ability to bind to glucose oxidase 
when exposed to fructose. This suggests that amino groups crucial for the binding 
may be highly susceptible to the sugar-induced alterations. However while some 
studies provide evidence for sugar-induced loss in binding of the antibodies to the 
antigens (Sasaki et al, 1993; Kennedy et al, 1994), others fail to find such 
inactivation (Morin et al, 1987; 1989; Dolhofer-Bleisener and Gerbitz, 1990). 
Apparently susceptibility of the crucial amino groups to sugar-induced 
modification vary considerably as also shown in case of several enzymes (Seidler, 
2005). Sell et al (1996) have also shown in an earlier study that collagen AGEs 
show species specific variations. 
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Complexing with antienzyme antibody/antibody fragments 
derived thereof protects both enzyme and antibody against 
glycation-induced inactivation. 
4.5. In vitro glycation of glucose oxidase 
Recent studies in our laboratory suggested that binding of specific anti-Cu, 
Zn-superoxide dismutase (Cu, Zn-SOD) antibodies remarkably protect the enzyme 
remarkably from glycation-induced alterations (Jabeen et al, 2006 (a)). The 
antibodies were also effective in restricting the inactivation resulting from 
exposure of the enzyme to glyoxal (Jabeen et al, 2006 (b)) and methylglyoxal 
(Jabeen et al, 2007). The findings were considered significant since available 
options of restricting the in vivo glycation reactions and the resulting damage are 
currently limited. Since antibodies themselves are modified by sugars, as shown in 
the first chapter of the thesis, it was considered of interest to investigate if 
complexing with specific antibodies protects both the antigenic enzyme and 
antibody against glycation. 
Aspergillus niger derived glucose oxidase was selected for this study in 
view of its potential high antigenicity in animals. The enzyme migrated as a single 
band in SDS-PAGE with an apparent molecular mass of 180 kDa (Figure 26). 
4.5.1. New Fluorescence 
Aspergillus niger glucose oxidase exposed to glucose, fructose and 
ribose was examined for the new fluorescence using an excitation wavelength 
of 370 nm and emission over the range of 380-500 nm. As shown in Figure 27, 
the emission spectra obtained gave maximum intensity at 440 nm, both for 
native and the sugar exposed glucose oxidase preparations. The magnitude of 
new fluorescence however was remarkably high in the samples incubated with 
the sugars; maximum increase was found in the enzyme exposed to ribose 
followed by the preparations treated with fructose and glucose. Several 
investigators have shown that reaction of sugars and aldehydes with protein 
leads to the formation of AGEs including pentosidine, a characteristic 
biomarker of glycation and accompanying autoxidation products, that show 
strong emission between 400 and 500 nm when excited at a wavelength of 370 
nm (Schmidt, 1990; Traverso et al, 1997). 
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Figure 26: SDS-PAGE of Aspergillus niger glucose oxidase. 
Glucose oxidase was subjected to SDS-PAGE in the presence of 
(3-mercaptoethanol as described in methods. Lane 1 and 2 contains the 
enzyme (12 \ig). Molecular mass markers C20 ug) were applied in lane 
3. The gels were silver-stained for visualization of protein bands. 
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Figure 27: Fluorescence spectra of native and glucose oxidase incubated with 
various sugars. 
Glucose oxidase samples incubated in 20 raM sodium phosphate 
buffer, pH 7.2 for 8 days at 37°C either alone ( ) or with glucose 
(- • ), fructose (••••) or ribose ( ) were taken for analysis. Samples 
were excited at 370 nm and emission range of 380-550 nm. The band 
width was 10 nm. 
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4.5.2. Protein bound carbonyl groups 
Carbonyl content is considered a reliable indicator of and is by far the most 
commonly used marker of protein oxidation and glycation. The yield of carbonyl 
groups however varies from protein to protein depending on the number/location 
of free amino groups present (Berlett and Stadtman, 1997; Beal, 2002). As also 
observed earlier with other proteins (Traverso et al, 1997), native glucose oxidase 
contained very small amount of carbonyl groups. The carbonyl content of glucose 
oxidase incubated with ribose, fructose or glucose is shown in Table II. Ribose and 
fructose caused the formation of far more carbonyl groups in the enzyme as 
compared to glucose. The relative reactivities of ribose, fructose and glucose in 
generating carbonyls substantiate the effects described in Figure 27. 
4.5.3. Electrophoretic Analysis 
Glucose oxidase incubated with glucose, fructose or ribose upto 8 days was 
also analysed by SDS-PAGE. The enzyme not exposed to the sugars migrated as a 
single sharp band (180 kd) but incubation with the sugars resulted in, a clear 
alteration in electrophoretic behaviour. This included a time dependent broadening 
decrease in intensity of the glucose oxidase band. The sugar-induced alterations 
appeared most prominent when the enzyme was incubated with ribose followed by 
fructose and glucose (Figure 28) apparently due to their relative reactivity in 
glycation reactions (Bunn and Higgins, 1981; Beswick and Harding, 1985; Yan 
and Harding, 1997). Glycation of proteins has been shown earlier to result in 
chemical modification, degradation and/or crosslinking of protein (Singh et al., 
2001). The observed decrease in the band intensity apparently results from such 
effects of sugars (Eble et al, 1983; Bouma et al, 2003). Appearance of small 
peptides could not be however noticed in the lanes containing enzyme incubated 
with the sugars. A decrease in protein mobility along, with the aggregated material 
was also observed on the top of the gel in the lanes. 
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Table II: Carbonyl group content of glucose oxidase incubated with 
various sugars. 
Sugar Carbonyl groups 
(nmoles/mg) 
None 2.2 ± 0.09 
Glucose 12.2 ±0.11 
Fructose 22.6 ±0.10 
Ribose 28.8 ±0.17 
All the values are mean ± S.D. for 3 experiments performed in duplicate. 
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Figuie 28: SDS-PAGE of glucose oxidase incubated reducing sugars. 
Glucose oxidase (1 mg/ml) was incubated with 100 mM sugars upto 8 
days in 20 mM phosphate buffer, pH 7.2 at 37°C. Lanes 1 contain 
glucose oxidase incubated alone for 8 days. Lanes 2, 3, 4, 5 and 6 
contain glucose oxidase incubated with glucose (A), fructose (B) or 
ribose (C) for 1, 3, 5, 6 and 8 days respectively. The samples were 
subjected to SDS-PAGE in presence of P-mercaptoethanol. The gels 
were silver stained for visualization of the protein bands. Twelve 
micrograms of each sample was loaded in respective lane. 
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4.5.4. Effect of incubation with sugars on the activity of glucose oxidase 
The effect of incubation with sugars on the activity of glucose oxidase is 
summarized in Figure 29. In agreement with previous observations with other 
enzymes (Arai et al., 1987; Yan and Harding 1997), incubation with the sugars at 
37°C resulted in marked decrease in the activity of the enzyme. Ribose caused 
maximum inactivation followed by fructose and glucose was least reactive in this 
regard. Open-chain forms are present in far higher concentrations in solution of 
ribose than those of fructose or glucose in contributing to the greater reactivity of 
former (Kaneto et al, 1994). Loss of enzyme activity at the end of day 8 was 96, 
88 and 71 percent respectively in the samples incubated with ribose, fructose and 
glucose. Glucose oxidase incubated in the absence of the sugar retained essentially 
complete activity. Several enzymes including superoxide dismutase and malate 
dehydrogenase undergo glycation-induced loss of biological activity (Heath et al, 
1996; Seidler, 2005; Jabeen et al, 2006 (a)) but rates of inactivation of various 
enzymes differ significantly. 
4.6. Preparation of F(ab)"2 and F(ab)' fragments 
4.6.1. Cleavage of anti-glucose oxidase-antibodies with pepsin and purification 
oftheF(aby2 
The IgG fraction isolated fron\. the immune sera by ammonium sulphate 
fractionation and DEAE-cellulose chromatography was subjected to proteolysis 
with pepsin to obtain F(ab)'2 fragments. The procedure described by Nisonoff et 
al, (1960) was followed for IgG cleavage by pepsin. Fragmentation of the IgG was 
studied by SDS-PAGE under reducing conditions (Figure 30). The gel shows the 
disappearance of the band corresponding to IgG with a parallel increase in the band 
of higher mobility (Figure 28, lane 5), suggesting the cleavage of IgG. The faster 
moving protein bands presumably correspond to degraded Fc' fragment. With a 
view to achieve the separation of F(ab)'2 generated from intact IgG and Fc' 
fragment, the mixture was incubated with Cu-IDA Sepharose and the supernatant 
subjected to SDS-PAGE. Figure 30, lane 6 shows a single band corresponding 
with the position between 29-20 kDa molecular mass marker bands, which is the 
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Figure 29: Enzyme activity of glucose oxidase incubated with reducing 
sugars. 
Glucose oxidase (lmg/ml) was incubated with 100 mM each of 
glucose (-•-), fructose (-^ r-) or ribose (-•-) separately for 8 days in 20 
mM phosphate buffer, pH 7.2 at 37°C. Control sample (-#-) contained 
glucose oxidase incubated alone upto 8 days. Glucose oxidase activity 
was determined as described in methods. Each value represents the 
average for three independent experiments performed in duplicate. 
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Figure 30: Purification of anti-glucose oxidase IgG and the F(ab)"2 fragment. 
Details of purification are discussed under methods. Lanes 1, 2, 3, 4, 5, 
6 contain molecular mass markers (20 ug), antiserum (18 jig), 20-40% 
ammonium sulphate fraction (18 ug), DEAE-cellulose purified IgG 
(18 ug), pepsin digest of IgG (18 ug) and IDA-Sepharose purified 
F(ab)'2 (14 fig) respectively. The samples were subjected to SDS-
PAGE in presence of (3-mercaptoethanol. The gels were silver stained 
for visualization of the protein bands, 
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approximate molecular weight of the fragment of heavy and light chain 
(Parham, 1986). 
4.6.2. Cleavage of anti-glucose oxidase-antibodies with papain and 
purification of Fab" 
Monomeric Fab" fragments were prepared and purified from 
immunized animals as detailed earlier in methods section 3.1.10. by the 
procedure of Catty and Raykundalia (1988) and SDS-PAGE (reducing) of 
the samples were run along with molecular weight markers. Figure 31 
shows that the papain treated IgG migrated as two bands. Since the 
electrophoresis was performed in presence of (3-mercaptoethanol, both the 
Fab' and Fc" are expected to dissociate as a result of reduction of 
disulphide linkage. The DEAE-cellulose purified F(ab)' monomer obtained 
by the cleavage of immunoglobulin with papain migrated as a single band 
with its position slightly lower than 29 kDa molecular mass marker band 
which is approximately the molecular weight of the fragment heavy and 
light chain. 
4.7. Effect of anti-glucose oxidase-IgG, F(ab)' 2 and F(ab)' on fructose-induced 
inactivation of glucose oxidase 
4.7'.1. Electrophoretic Behaviour 
Figure 32 shows the SDS-PAGE of glucose oxidase incubated with 
fructose in the presence or absence of the antibody. As also shown earlier glucose 
oxidase incubated with fructose migrated as a diffuse faint band, a fraction of 
which migrating faster than the principal enzyme band. Also, a significant increase 
in the aggregate material retained at the top of the gel was evident (lane 2). Lanes 
containing glucose oxidase incubated with fructose in the presence of increasing 
quantities of antibody showed that the sugar-induced alterations in glucose oxidase 
were restricted. As apparent from the figure, the protection appeared to increase 
with increasing concentration of the antibody and was most remarkable when the 
antibody/enzyme ratio was 10. 
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Figure 31: Purification of anti-glucose oxidase IgG and the F(ab)" fragment. 
Details of purification are discussed under methods. Lanes 1, 2, 3, 4, 
5, 6 contain antiserum (18 jag), 20-40% ammonium sulphate fraction 
(18 (ig), DEAE-Cellulose purified IgG (18 ug), papain digest (18 ug), 
DEAE-cellulose purified F(ab)' (14 ug) and molecular mass markers 
(20 ug) respectively. The samples were subjected to SDS-PAGE in 
presence of p-mercaptoethanol. The gels were silver stained for 
visualization of the protein bands. 
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Figure 32: SDS-PAGE of anti-glucose oxidase IgG showing protection 
against fructose-induced inactivation of glucose oxidase. 
Anti-glucose oxidase-IgG in molar ratio between 1:1-1:10 were 
included in incubation mixtures containing glucose oxidase in 20 mM 
phosphate buffer, pH 7.2 with 100 mM fructose upto 8 days at 37°C. 
Lane 1 contains glucose oxidase (14 ug) incubated alone. Lane 2 
contains glucose oxidase incubated with fructose alone (14 ug) while 
lanes 3, 4, 5 and 6 contain glucose oxidase incubated with fructose in 
the presence of anti-glucose oxidase-IgG in the molar ratio as 1:1, 
1:2, 1:5, 1:10 respectively (20 ug). The samples were subjected to 
SDS-PAGE in presence of (3-mercaptoethanol. The gels were silver 
stained for visualization of the protein bands. 
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4.7.2. Activity of glucose oxidase 
Incubation with fructose resulted in a rapid inactivation of glucose oxidase 
and the enzyme lost almost 90 percent activity after incubation with fructose for 8 
days. Intact anti-glucose oxidase-IgG, F(ab)r2 and F(ab)" fragments were all 
protective and protection increased with increase in their concentration; maximum 
protection was evident when the molar ratios of IgG/fragments and enzyme was 10 
(Figure 33). While the observed protection with IgG and the fragments was 
comparable, F(ab)' appeared somewhat superior, providing upto 85% protection at 
10:1 antibody/enzyme molar ratio. 
A remarkable protection against sugar-induced degradation and inactivation 
of glucose oxidase was provided by the anti-enzyme-antibodies (Figure 32 & 33). 
The inactivation or degradation of glucose oxidase on incubation with sugars was 
nearly completely prevented in the presence of antibodies, F(ab)'2 or F(ab)' at a 
molar excess 10, indicating their ability to prevent damage caused by sugars. 
These observations are in agreement with those of Jabeen et al (2006 (a)) 
who too observed upto 90% of protection against inactivation of Cu, Zn-SOD by 
its antibodies when antibody/enzyme molar ratio was taken upto 10:1. A number of 
studies on several antibodies have shown their role as chaperones and facilitate the 
refolding and/or aggregation of proteins and enzymes (Seilder, 2005). Although 
the exact mechanism for the protective role of against glycation needs to be 
elucidated, previous studies suggest that antibodies can act as chaperones under 
specific conditions and can facilitate folding of protein antigens (Ermolenko et al, 
2004). 
4.8. Effect of anti-glucose oxidase-IgG and the fragments derived thereof on 
the inactivation of glucose oxidase by other sugars 
4.8.1. Activity of glucose oxidase 
As shown in Figure 34, glucose oxidase incubated alone with various sugars 
showed a marked decrease in the activity in eight days. Ribose was most inhibitory 
and lead to a 96 percent decrease in activity of glucose oxidase while fructose and 
glucose caused a loss of 88 and 71 percent activity respectively. As evident 
from the figure, anti-glucose oxidase antibodies and the F(ab)7F(ab),2 exerted 
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Figure 33: Protection by antiglucose oxidase IgG, F(ab)' and F(ab)^ 2 derived 
thereof against fructose induced inactivation of glucose oxidase. 
Anti-glucose oxidase-IgG (j§|), F(ab)'2 (EO)and Fab' (0) in molar ratio 
between 1:1-1:10 were included in incubation mixtures containing 
glucose oxidase in 20 mM phosphate buffer, pH 7.2 with 100 mM 
fructose upto 8 days at 37 C. Glucose oxidase was also incubated 
with 100 mM fructose ( • ) alone upto 8 days as well while control 
sample (Q) contained glucose oxidase incubated alone upto 8 days. 
Glucose oxidase activity was determined as described in methods. 
Each value represents the average for three independent experiments 
performed in duplicate. 
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Figure 34: Protection by anti-glucose oxidase-IgG, F(ab)"2 and F(ab)' derived 
thereof against the loss of glucose oxidase activity induced by 
sugars. 
Glucose oxidase was incubated with 100 mM of various sugars in the 
absence ( 0 ) or presence of 10 molar excess of IgG ( H ), F(ab)'2 
(H)or F(ab)' (0) for 8 days at 37°C and glucose oxidase activity was 
determined. Control sample (£3) contained glucose oxidase incubated 
alone without (sugar or antibody/ antibody fragments). Glucose 
oxidase activity was determined as described in methods. Each value 
represents the average for three independent experiments performed 
in duplicate. 
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remarkable protective effect against enzyme inactivation induced by the sugars. Under 
the conditions used, protection afforded by intact antibodies, F(ab)*2 and F(ab)" 
respectively was 90, 87, 80 percent for glucose, 85, 82, 78 percent for fructose and 80, 
75, 70 percent for ribose. The IgGs used in the study were obtained by purification on 
a DEAE-cellulose column and comprise the entire IgG class. Although the titre of the 
antibodies in the immune serum was very high, it could not be ascertained as to what 
percentage of the IgGs were glucose oxidase-specific. The protection provided by the 
antibodies/antibody fragments against the sugar-induced alterations was specific since 
non-specific IgG were not protective. Thus, results show that specific polyclonal 
antibodies/F(ab)VF(aby protected glucose oxidase against sugar-induced inactivation. 
It is now well established that glycation by sugars and various dicarbonyls are activity 
involved in glycation reactions both in vitro and in vivo (Syrovy, 1992; Kang, 2003). 
Several enzymes complexed with monoclonal/polyclonal antibodies exhibit enhanced 
stability against various forms of inactivation (Saleemuddin, 1999). Several possible 
explanations can be suggested to explain the protective effect of antibodies. Owing to 
their large size antibodies may sterically hinder the aggregation upon binding to the 
antigen molecules as in case of P-amyloid peptide, whose aggregation is inhibited both 
by antibodies raised against the short N-terminal peptide fragment and those against 
13-28 residues (Legleiter, 2004). Alternatively, binding of antibodies may shift 
equilibrium between unfolded and native conformations of the protein antigen towards 
the native form or lower the activation barrier through stabilization of the folded 
transition state (Ermolenko et al, 2004). 
4.8.2. Effect of various sugars on the glucose oxidase complexed with anti-glucose 
oxidase-antibodies and antibody fragments 
Some reports from other workers (Sasaki el ai, 1993; Kennedy et ai, 1994) 
suggest that antibodies undergo sugar-induced alterations including loss of ability to 
bind to antigens. Experiments were performed to investigate if antibodies pre-
complexed with glucose oxidase also undergo such modifications. It has been shown 
in the earlier part of the thesis that immunoglobulin undergoes characterisitic sugar-
induced alterations including electrophoretic mobility and spectral properties. As 
evident from the Figure 35, the SDS-PAGE of antibody-glucose oxidase complex did 
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Figure 35: Protection by anti-glucose oxidase-IgG against the inactivation of 
glucose oxidase induced by reducing sugars. 
Glucose oxidase was incubated with 100 mM of reducing sugars and 
10-fold molar excess antibody for 8 days at 37°C and subjected to SDS-
PAGE in presence of P-mercaptoethanol. Lanes 1, 3, 5 of each panel 
contains glucose oxidase (14 ug), anti-glucose oxidase-IgG (18 jag) or 
the mixture of glucose oxidase and anti- glucose oxidase IgG (20 ug) 
incubated without sugar for 8 days. Lanes 2, 4, 6 contain the above 
listed incubated with glucose (A), fructose (B) or ribose (C). The gels 
were silver stained for visualization of the protein bands. 
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not exhibit significant alteration after incubation with glucose, fructose and ribose 
(Figure 35, lanes 5 and 6). In contrast, when incubated alone with the sugars, the 
antibodies showed remarkable variations in electrophoretic behaviour. As shown in 
the figure, there was observed a clear decrease in the intensity of small molecular 
weight and large molecular weight bands with the former almost disappearing in 
samples incubated with fructose and ribose. Formation of aggregated materia! that 
appeared as diffused dark staining material at or close to the top of gel was also 
evident. Comparable protection against the sugar-induced alterations was also 
observed when glucose oxidase was complexed either with F(ab)' or F(ab)'2 prior to 
incubation with sugars (Figure 36 and 37). Both F(ab)' and F(ab)x2 migrated as bands 
corresponding to molecular weight of 50,000, close to that of the low molecular 
weight polypeptide of the IgG. Incubation of the antibody fragments with fructose and 
ribose resulted in remarkable decrease in staining intensity accompanied by diffusion 
of the band and formation of aggregate. The alteration was most prominent in the 
samples incubated with ribose (Figure 36 and 37). A comparison of the lanes 5 and 6 
of the Figure 35, 36 and 37 suggest that both the fragments and the intact IgG were 
remarkably protected against the sugar-induced alterations. 
Incubation of glucose oxidase complexed with anti-glucose 
oxidase-antibodies, F(ab) '2 or F(ab)" with sugars resulted in no 
significant alteration in the electrophoretic behaviour either of the 
enzyme antigen or the antibody. On the other hand glucose oxidase, the 
intact antibody, F(ab)v2 or F(ab)' incubated separately with the sugar 
showed appreciable decrease in band intensity along with the 
aggregated material. Intermolecular cross-linking of the enzyme, the 
antibody or the antibody fragments may result in the formation of 
aggregates, which maybe too large to enter the gel pores and hence may 
not be detected on the gels. In these experiments also ribose appeared 
most reactive compared to other sugars. Control samples i.e. incubated 
in the absence of the sugar exhibited little/no 
fragmentation/aggregation under the conditions employed. The level of 
protection achieved with intact antibodies, F(ab) '2 and F(ab)' appeared 
comparable. 
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Figure 36: Protection by anti-glucose oxidase-F(ab)'2 against the 
inactivation of glucose oxidase induced by reducing sugars. 
Glucose oxidase was incubated with 100 mM of reducing sugars and 
10-fold molar excess F(ab)'2 for 8 days at 37°C and subjected to 
SDS-PAGE in presence of |3-mercaptoethanol. Lanes 1, 3, 5 of each 
panel contains glucose oxidase (14 ug), anti-glucose oxidase-F(ab)'2 
(18 ng) or the mixture of glucose oxidase and anti- glucose oxidase-
F(ab)'2 (20 jig) incubated without either sugar for 8 days. Lanes 2, 4, 
6 contain the above listed incubated with glucose (A), fructose (B) or 
ribose (C). The gels were silver stained for visualization of the protein 
bands. 
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Figure 37: Protection by anti-glucose oxidase-F(aby against the inactivation 
of glucose oxidase induced by reducing sugars. 
Glucose oxidase was incubated with 100 raM of reducing sugars and 
10-fold molar excess F(ab)' for 8 days at 37°C and subjected to SDS-
PAGE in presence of f3-mercaptoethanol. Lanes 1, 3, 5 of each panel 
contains glucose oxidase (14 ug), anti-glucose oxidase-F(ab)' (18 ug) 
or the mixture of glucose oxidase and anti- glucose oxidase- F(ab)' 
(20 ug) incubated without either sugar for 8 days. Lanes 2, 4, 6 
contain the above listed incubated with glucose (A), fructose (B) or 
ribose (C). The gels were silver stained for visualization of the 
protein bands. 
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The observations suggest a potential role of specific anti-enzyme-antibodies, 
F(ab)<2 or F(ab)' in preventing the glycation-mediated inactivation of glucose 
oxidase. We assume that binding of antibody/antibody fragments prevents 
conformational change in the enzyme and exposure to the glycation agents as well 
as consequent modification and inactivation of the enzyme. It has been shown from 
this laboratory that anti-Cu,Zn-superoxide antibodies protect the enzyme against 
inactivation induced by some sugars (Jabeen et al, 2006 (a)). The antibodies also 
protected the enzyme from undergoing inactivation and aggregation induced by 
glyoxal (Jabeen et al, 2007) and methyl glyoxal (Jabeen et al, 2006 (b)). In a 
previous study, antibodies were shown to bind at strategic protein-folding-
initiation sites leading to the correct refolding of clustered epitopes (Solomon and 
Schwartz, 1995). Protection observed against the glycation-induced alterations in 
the antibody and antibody fragment when these are present as complex with the 
enzyme is interesting and indicate their potential as antiglycation agents (Figures 
35, 36 & 37). Bivalent antibodies however have the inherent risk of crosslinking 
and aggregating the antigenic protein and may not be suitable for immunotherapy 
directed at the soluble proteins. The protection provided by the monomeric F(ab)' 
fragment suggests that bivalent antibodies are not essential for protection against 
glycation (Figures 34, 35, 36 & 37). In an earlier study it has been shown that 
binding of F(ab)' monomer to bromelain improves the stability of the enzyme 
against denaturation (Gupta et al, 2003). 
4.9. Conclusion and implications of the study 
It is now recognized that glycation contributes remarkably to the 
complications associated with diabetes and related disorders. Studies have shown 
that glycated protein loose biological activity (Vlassara et al, 1994; Brownlee, 
2001). A large number of enzymes undergo remarkable inactivation in response to 
glycation and the mechanism of loss of biological activity has received 
considerable attention. The sugars induce unfolding, aggregation and inactivation 
either by modifying the active site or by reacting with residues distinct from active 
site involving more subtle and complex mechanisms including compaction, loss of 
protein flexibility and protein aggregation (Nishikawa et al, 2000; Rosea et al, 
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2005). Studies have shown that since it is the open chained forms of the sugars 
that are reactive towards the amino groups and those with more stable open chains 
are more reactive (Monnier et al, 1979; Bunn and Higgins 1981). In fact the open 
chain form of glucose constitutes just 0.002% in solution thus making it the least 
reactive as compared to other reducing sugars (Bunn et al, 1978; Bunn and 
Higgins 1981). 
A number of agents that prevent or restrict glycation reactions are therefore 
being evaluated for therapy against such disorders. These include those that 
compete with amino groups of proteins for reaction with the sugars, bind to protein 
and prevent access to amino groups, mop up the open chain form of the sugar or 
restrict their further transformation to AGEs (Harding and Ganea, 2006). a-
Crystallin occurring in the eye lens and various enzymes against heat induced-
inactivation/aggregation (Horwitz, 1992) and more recently against glycation-
induced alterations (Ganea and Harding, 1996; Blakytny and Harding, 1997; 
Derham and Harding; 2002) suggesting that strengthening of the crystalline-
mediated stabilization of protein could be an effective strategy in combating 
glycation-related complications. A number of studies on several antibodies have 
shown their role as chaperones and facilitating the refolding and/or aggregation of 
proteins and enzymes (Ermolenko et al, 2004). 
A remarkable protection against sugar-induced inactivation of glucose 
oxidase was provided by polyclonal anti-glucose oxidase-antibodies (Figures 
29, 30 and 32). The inactivation or degradation of glucose oxidase on 
incubation with sugars was nearly completely prevented in the presence of 
antibodies indicating their ability to prevent damage caused by sugars. The 
purified antibodies exerted maximum protective effect at molar ratio of 1:10 
(enzyme/antibody) (Figures 29 and 30). Moreover specific anti-glucose 
oxidase-F(ab),2 oi* F(ab)' fragments were also effective in suppressing 
aggregation and inactivation induced by the reducing sugars (Figures 31, 33 and 
34). Since F(ab)' monomers provided better protection to the enzyme, rather 
than cross-linking and aggregation by the bifunctional anti-enzyme-IgG, they 
may play an important role in restricting the sugar-induced damage. 
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Our earlier studies have shown that antibodies raised against the labile 
region of RNase were more protective then those raised against the N-terminal 
peptide (Yonus et al, 2001). The labile region specific antibodies also improved 
the thermal stability of a mutant RNase in which the labile region contained an 
altered amino acid (Yonus et al, 2002). Studies with anti-lysozyme antibodies 
however suggest that binding of a monoclonal antibody raised against the native 
enzyme improves the thermal stability of the enzyme antigen even if they do not 
recognize epitopes located close to the mutation site. The D67H mutation of the 
human lysozyme related to systemic amylodosis undergoes partial unfolding and 
aggregation with a melting temperature 10°C lower than that of the native enzyme 
(Canet et al, 2002). Binding of c-Ab-HUL6 increased the melting temperature of 
the enzyme by 15 °C although the residue whose mutation leads to the 
destabilization and aggregation does not make any contact with the antibody 
(Dumoulin et al, 2003). It may not be therefore essential to identify the specific 
epitope of the target protein for raising antibodies although such a selection may 
improve the effectiveness of the antibody. 
Specific anti-enzyme antibodies may actually restrict the process of 
glycation or prevent inactivation without interfering with the initial reaction of 
sugars. In spite of remarkable differences in reactivity, nearly all surface amino 
groups of proteins can be glycated under appropriate conditions so it is unlikely 
that the antibodies restrict glycation of proteins merely by masking the susceptible 
sites (Iberg and Fluckiger, 1986). Complexation with antibodies/antibody 
fragments results in a remarkable improvement in the ability of a large number of 
enzymes to resist various forms of inactivation (Saleemuddin, 1999; Turkova, 
1999), and the present study shows that the anti-enzyme-antibodies can be highly 
effective against glycation. X-Ray study of several antibody-protein antigen 
complexes has shown that antibody binding induces conformational changes in the 
liable regions of the antigen molecule. Ulbrich-Hoffman et al, (1993) and 
coworkers proposed that enzymes might contain specific regions where unfolding 
of the molecule may begin and blocking of such regions may lead to restriction of 
unfolding and enhancement in the stabilization of enzyme. 
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Antibodies may have an advantage as antiglycation agents since specific 
antibodies can be readily raised against any enzyme. Immunotherapy for the 
prevention of aggregation of (3-amyloid peptide in Alzheimer's disease (Solomon, 
2003) and prion protein has been envisaged (White et ai, 2003). Formation of an 
immunocomplex with antibodies could provide a general and convenient method 
of stabilization the conformation of enzymes. One can also envisage the possibility 
of using antibodies for increasing the effectiveness of the administered enzyme 
during enzyme therapy. Consequently, numerous attempts to increase the 
therapeutic potential of enzyme by designing strategies have been made. One 
major approach is chemical modification like coupling of polyethylene glycol 
(PEG) to the enzyme. Encapsulation of enzymes in liposomes represents 
alternative approach. Liposomes hold a great promise in the treatment of diseases 
associated with oxidative stress (Muzykantov, 2001). Another approach is to 
exploit cell's own transport mechanism for example, receptor mediated 
endocytosis for enzyme delivery. Several receptors like transferring have been 
exploited to deliver both proteins and nucleic acids to a number of different tissue 
types. A further method is to use series of small protein domains, termed protein 
transduction domain (PTDs) to deliver full-length biologically active proteins into 
cells (Clement et ai, 1998). Thus, this study opens a window to the potential of 
immunotherapy against glycation-induced alterations in proteins. 
Immunological detection of glycated proteins in vitro. 
4.10. Preparation of fructated-BSA as antigen 
BSA incubated with 100 mM fructose in 20 mM phosphate buffer pH 7.2, 
for 8 days was analyzed by SDS-PAGE in presence of the thiol reductant (3-
mercaptoethanol (Figure 38). The fructose treated sample migrated as a diffuse 
band of low intensity as compared to that of the control sample. This suggested 
modification by BSA degradation and/or crosslinking (Singh et al, 2001). This 
could also be explained on the basis that polymerized species represent 
polycomponent mixtures which make smears with low mobility of protein under 
SDS-PAGE (Misksik and Deyl, 1997). 
The UV spectrum of both native and fructose-treated BSA showed 
maximum absorbance at 280 nm. Treatment with fructose brought about increase 
in the absorbance of BSA (Figure 39). The UV absorption spectrum showing 
hyperchromicity is indicative that hydrophobic groups of the fructose-treated BSA 
maybe more exposed as compared to those of native protein due to unfolding 
and/or fragmentation of the molecule (Hunt et al, 1988). 
The fructose treated BSA was further analyzed for new fluorescence using 
an excitation wavelength of 370 nm and emission over the range of 370-550 nm. 
As shown in Figure 40, the spectrum showed maximum emission at 440 nm, like 
the native BSA but showed remarkable increase in new fluorescence. 
Development of the new fluorescence is probably related to formation of new 
fluorophores. A marked increase in new fluorescence has shown to be 
characteristic of glycated proteins (Sensi et al, 1992). The increase in the 
magnitude of the fluorescence is also indicative of high reactivity of fructose 
causing acceralated conversion of the Amadori groups to fluorescent structures 
(Suarez et al, 1989). 
4.11. Immunogenicity of fructated-BSA and cross reactivity of antibodies 
Fructated-BSA used as an antigen for the study was quite immunogenic 
and readily induced antibody formation in rabbits. In Figure 41, sharp precipitin 
lines were obtained on immunodiffusion of the antiserum against fructated-BSA, 
fructated-ovalbumin and fructated-glucose oxidase. The precipitin lines obtained 
showed that antiserum raised against the fructated-BSA readily crossreacted with 
97 
Figure 38: Effect of incubation on BSA with fructose to prepare antigenic 
fructated-BSA. 
BSA was incubated with 100 mM fructose as described in the text. 
Lane 1 contains BSA incubated without fructose for 8 days. Lanes 2 
and 3 contain BSA samples incubated with fructose for 8 days. The 
samples were subjected to SDS-PAGE in presence of (3-
mercaptoethanol. The gels were silver stained for visualization of 
protein bands. Twelve micrograms of each sample was loaded in 
respective each. 
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ure 39: Ultraviolet spectra of native and fructose treated BSA. 
UV spectra of native ( ) and fructose (•••••) treated samples of BSA 
in 20 mM sodium phosphate buffer, pH 7.2 for 8 days at 37°C were 
taken for analysis. The pathlength was 1 cm. 
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Figure 40: Fluorescence spectra of native and fructose treated BSA. 
Fluorescence spectra of native ( ) and fructose ( — • ) treated 
samples of BSA in 20 mM sodium phosphate buffer, pH 7.2 for 8 days 
at 37°C were observed for analysis. Samples were excited at 370 nm 
and emission range of 380-550 nm and band width was 10 nm. 
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Figure 41: Ouchterlony Double Immunodiffusion of different antigens 
against anti-fructated-BSA antiserum. 
Rabbits were immunized with fructated-BSA and the antiserum 
obtained was fractionated to purify antibodies. Immunodiffusion was 
performed in 1% agarose gel prepared in normal saline. The central 
well contained 30 ul of antiserum, while wells 1, 2 and 3 contained 
15 u.g of fructated-ovalbumin, fructated-glucose oxidase and 
fructated-BSA respectively. 
101 

all the three fructated proteins used indicating presence of antibodies that 
recognized groups generated as a result of reaction of protein with fructose (Jan et 
al, 2002; 2004). 
Preimmunized and immunized sera were tested with three antigens for titre 
determination of fructosyl group specific antibody in the antisera. As shown in 
Figure 42, serial dilution of immunized sera was applied in the wells coated with 
fructated-ovalbumin, BSA and fructated-BSA. Immunized sera showed 
appreciable binding with all the fructated proteins giving a good antibody titre, 
Significantly high titre was observed in case of fructated-BSA as compared to 
BSA that was not exposed to fructose indicating presence of additional antibodies 
recognizing epitopes of groups generated as a result of reaction of fructose with 
the protein (Jan et al, 2002; Vay et al, 2000). 
4.12. Purification of anti-(fructosyI group)-antibodies 
For the purification of antibodies from the sera of rabbits immunized with 
fructated-BSA, fructated-ovalbumin bound CH-Sepharose-4B matrix was used as 
described in the method section 3.3.2. (Porath et al, 1967). The antiserum was 
applied to the matrix which was equilibrated with 20 mM phosphate buffered 
saline pH 7.2. Bound antibodies were eluted with 0.1 M glycine/ HC1 buffer and 
the eluate was immediately neutralized with 1 M Tris buffer. The homogeneity of 
antibody was ascertained by SDS-PAGE. Antiserum contains several bands 
including those of the IgG (Figure 43, lane 1). Affinity chromatography resulted 
in purification of IgG and two bands were visible on the gel of purified antibody 
corresponding to the heavy (50 kDa) and light chains (25 kDa) (Figure 43, lane 2). 
4.13. Competition ELISA 
To further illustrate on the presence of antibodies in the immune sera as 
well as their specificity of antibodies against the fructosyl group purified from it, 
competition ELISA of the preimmune, the immune sera as well as affinity purified 
anti-(fructosyl group)-antibodies was performed (Figure 44). Immune complexes 
were formed using fructated ovalbumin as an antigen as described earlier by 
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Figure 42: Cross Reactivity of the anti-fructated-BSA-antibodies with 
different antigens. 
Native BSA (-A- ), fructated-BSA ( -u-) or fructated-ovalbumin 
( -«— ) (0.5 jig/well) were coated on the ELISA plate and were 
processed for the direct binding ELISA as described in the text. 
Various dilutions of the pre immune sera (•••••) and fructated-BSA-
specific antisera were added to the plate. Finally the plate was 
developed with the colouring agent and absorbance of the coloured 
complex was measured at 410 nm. 
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Figure 43: SDS-PAGE of affinity purified anti-(fructosyI group)-antibodies. 
Antiserum raised against fructated-BSA was affinity purified on a 
colmun of CH-Sepharose-4B coupled with fructated-ovalbumin. The 
antiserum and the ffuctated samples were subjected to SDS-PAGE. 
Lanes 1, 2 and 3 contain antiserum (18 ug), CH-Sepharose-4B 
purified anti-(fructosyl group)-antibodies (12 ug) and molecular mass 
markers (20 ug). The gels were silver stained for visualization of 
protein bands. 
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Figure 44: Competition ELISA of the anti-(fructosyI group)-antibodies with 
fructated-ovalbumin. 
The antigenic specificity of the antibodies was determined by 
Competitive ELISA. Fructated-ovalbumin (0-20 pg/ml) was mixed 
with a 100 ul of preimmune serum ( - • - ), antiserum ( - • - ) or IgG 
(-A-) (1:100 dilution). The immune complex thus formed was coated 
on the remaining steps were the same as in Direct Binding ELISA. 
Finally the plate was developed with the colouring agent and 
absorbance of the coloured complex was measured at 410 nm. 
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mixing appropriate amounts of antisera with fructated-ovalbumin. The samples 
were then applied on a microtitre plate precoated with fructated-BSA. The 
inhibition caused by antiserum and prepared antibodies was 48% and 88% 
respectively at the maximum inhibitor concentration used. This confirms the 
specificity of antibodies purified on the affinity column to the fructosyl group of 
fructated-ovalbumin (Mansoor et al., 2005). 
4.14. Specificity of the anti-(fructosyI group)-antibody 
4.14.1. SDS-PAGE of human IgG incubated with different sugars 
SDS-PAGE analysis of human IgG incubated with 100 mM glucose, 
galactose, fructose or ribose for 8 days as shown in Figure 45. As observed earlier 
with other fructose-treated immunoglobulins, incubation of human IgG with 
sugars resulted in decrease of the intensity of bands which varied with different 
sugars. The alteration was maximal in case of ribose followed by fructose, 
galactose and glucose. Formation of aggregates was also observed. As shown in 
previous chapters (I & II) these studies indicate that glycation by fructose results 
in chemical modification, degradation and/or crosslinking of the IgGs as observed 
earlier with other proteins (Singh et al, 2001). 
4.14.2. Immunochemical studies 
In order to determine the specificity of the anti-(fructosyl group)-
antibodies, cross reactivity with human IgG incubated with various sugars was 
investigated by ELISA (Figure 45). There was no significant binding with the 
immunoglobulin incubated with glucose, galactose or ribose. Human IgG 
incubated with fructose however showed remarkable binding of the antibody. 
The specificity of the antibodies was further examined by 
immunoblotting. IgG incubated with various sugars was subjected to 
electrophoresis and electroblotted on nitrocelluie.se membrane. A sharp 
band was visible in lane 4 (Figure 46) which contain human IgG exposed 
to fructose. No bands appeared in the control lane as well as those 
containing human IgG treated with glucose, galactose or ribose. 
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Figure 45: Binding of anti-(fructosyl group)-antibody to human IgG 
incubated with various sugars. 
Human IgG was incubated in 20 mM phosphate buffer, pH 7.2 with 
100 mM glucose, galactose, fructose or ribose at 37°C for 8 days 
under aerobic conditions and subjected to ELISA using the anti-
(fructosyl group)-antibodies. IgG incubated without sugars under the 
same conditions served as control. Anti-(fructosyl group)-antibody 
was used as the first antibody at a 1:500 dilution. Inset: The samples 
were also subjected to SDS-PAGE in presence of p-mercaptoethanol 
and silver stained for visualization of protein bands. Lane 1 contains 
control sample while lanes 2, 3, 4 and 5 contain IgG incubated with 
glucose, galactose, fructose or ribose. Twelve micrograms of the 
each sample was loaded in respective lane. 
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Figure 46: Western blot analysis using anti-(fructosyl group) antibody. 
Human IgG incubated with various sugars was subjected to SDS-
PAGE and blotted to a nitrocellulose membrane. Lane 1 contains 
human IgG incubated without sugar while lanes 2, 3, 4 and 5 contain 
IgG incubated with 100 mM glucose, galactose, fructose or ribose at 
37°C for 8 days respectively. Seven micrograms of each sample was 
loaded in respective lane. The protein bands were probed by using 
anti-(fructosyl group)-antibody as described in the text. The 
membrane was developed using KODAK XR film. 
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This suggests that the antibody recognizes only the fructosyl group. The 
antibodies raised against fructated-lysine by Miyazawa and coworkers (1998) 
were also specific to fructose treated BSA but not to those treated with glucose, 
galactose or ribose. Comparable specificity of anti-AGE-antibodies has been 
reported by other workers also, Nagai et al, (2002) raised polyclonal anti-(non-
carboxymethyl-glycoaldehyde)-antibodies specific for glycoaldehyde-modified 
proteins. These antibodies specifically bound glycoaldehyde-modified-BSA but 
not with BSA modified by other aldehydes such as glucose, glyoxal, 
methylglyoxal and 3-deoxyglucosone. 
4.15. ELISA analysis of fructation of IgG from various sources 
Works of various groups boast of production of polyclonal and 
monoclonal anti-AGE-antibodies which are exclusively specific to their antigenic 
adducts thus acting as a vital tool in examining not only presence but also their 
levels in various in vitro sugar-treated proteins as well as in samples from diabetic 
subjects (Cohen and Hud, 1989; Myint et al, 1995; Koito et al, 2004). 
Experiments were therefore performed using anti-(fructosyl group)-antibody to 
detect the level of fructation in IgG from various mammalian and avian sources 
undergone in vitro incubation with fructose using direct binding ELISA(Figure 
47). Maximum binding was observed in hen IgY and minimum in case of goat 
IgG. The differences in binding of the antibodies support the high susceptibility to 
glycation by fructose of hen IgY and recalcitrance of the ^oat IgG. 
4.16. Effect of uninterrupted and interrupted incubation with fructose on 
IgG glycation 
A study by Khalifah et al, (1996) has shown that ribose is highly reactive 
in glycation reactions but is inhibitory at high concentrations, when the proteins 
were reacted with the sugar initially and incubation continued after removal of 
the sugar, AGE formation was remarkably fast. Formation of AGE was far slow 
when the reaction was carried out without interruption. 
In order to investigate if fructose exposed proteins also undergo similar 
modification, the human IgG were incubated with fructose and subjected to 
109 
Figure 47: Fructation of IgG isolated from sera of various animals. 
IgG isolated from goat, human, rabbit, mouse, buffalo and hen egg 
yolk in 20 mM phosphate buffer, pH 7.2 were incubated with 100 
mM glucose, galactose, fructose or ribose at 37°C for 8 days under 
aerobic conditions. IgG incubated without sugars under the same 
conditions served as control. Quantification of fructation of IgG from 
various sources was performed using Direct Binding ELISA with 
these antibodies. Anti-(fructosyl group)-antibody was used as the 
first antibody at a 1:500 dilution. 
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uninterrupted and interrupted incubation with the sugar. The samples incubated 
for eight days were then subjected to SDS-PAGE in the presence of |3-
mercaptoethanol (Figure 48). A clear alteration in electrophoretic behaviour 
was evident in samples incubated with fructose (laries 2, 3 and 4). A time-
dependent broadening of the IgG band and decrease in band intensity in all 
samples was observed. The fructose-induced alterations however appeared 
somewhat more prominent in sample subjected to interrupted incubation with 
fructose. The differences were not as remarkable as those observed by Khalifah 
et al. (1996) with ribose. 
The fructose treated samples were further characterized for their new 
fluorescence using an excitation wavelength of 370 nm and emission over the 
range of 370-550 nm. As shown in Figure 49, the emission spectra obtained 
gave maximum intensity at 440 nm for both native and fructose treated 
samples. However fructose treated IgG showed marked increase in the 
magnitude of the new fluorescence with maximum increase in samples 
subjected to interrupted incubation followed samples subjected to 
uninterrupted glycation and that incubated with fructose for five days. 
Studies carried out over the years have shown that glycation results 
in the modification/ crosslinking of proteins and formation of various 
fluorophores (Ahmed, 2005). Figure 48 and 49 suggest crosslinking and 
development of new fluorophores in the IgG treated with fructose (Eble, 
1983; Sensi, 1992). However the excessive broadening of bands and 
increase in new fluorescence in case of interrupted incubation is consistent 
with an earlier interrupted ribose experiment with BSA by Odetti et al. 
(1992). Mc Pherson et al. (1988) found a similar increase in the 
fluorescence and crosslinking of prefructated ribonuclease. His 
observation revealed that marked paradoxical inhibition of overall AGE 
formation by high concentration of fructose which could be reversed by 
the dialysis of initially modified protein, resulting in further rapid 
modification of proteins (Wells-Knecht et al, 1995). Similarly studies by 
Khalifah et al. (1996) showed that inhibition is not due to accumulation 
cf dialyzable inhibitory intermediates during the initial glycation 
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Figure 48: SDS-PAGE of human IgG subjected to uninterrupted and 
interrupted incubation with fructose. 
Human IgG incubated in 20 raM phosphate buffer, pH 7.2 with 100 
mM fructose at 37°C for 8 days. After 5 days, one fraction of reaction 
mixture was taken out and dialyzed extensively and then reincubated 
for further 3 days under same sterile aerobic conditions in the absence 
of fructose. The second fraction was incubated without interruption. 
IgG incubated fructose uninterrupted under the same conditions 
served as control. Lane 1 contains control sample while lane 2 
contains IgG incubated with fructose for 5 days. Lanes 3 and 4 
contains IgG incubated uninterrupted with fructose for 8 days and that 
incubated without fructose for the last 3 days respectively. The 
samples were subjected to SDS-PAGE in presence of f3-
mercaptoethanol. The gels were silver stained for visualization of 
protein bands. Twelve micrograms of each sample was loaded in 
respective lane. 
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Figure 49: Fluorescence spectra of native and fructose treated human IgG. 
Control human IgG ( ), the samples incubated with fructose for 5 
days (— •) and those continued with the incubation for further 3 days 
in the absence (interrupted) ( — - ) or presence (uninteruupted) 
( ) of fructose was used. See legend to Figure 48 for details. 
Fluorescence spectra of native and modified preparations in 20 raM 
sodium phosphate buffer were taken at pH 7.4. Samples were excited 
at 370 nm and emission range of 400-500 nm and band width was 10 
nm. 
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since dialysis of 24 hours modified protein followed by addition of different 
concentration of fresh ribose induces same degree of inhibition. 
4.16.1. ELISA analysis of'/nictation in human IgG subjected to uninterrupted 
and interrupted incubation with fructose 
IgG isolated from human sera was subjected to uninterrupted and 
interrupted incubation with 100 mM fructose for 8 day; and presence of material 
reactive to anti-(fructosyl group)-antibody was quantified by ELISA. As seen in 
Figure 50, all the samples subjected to incubation with fructose showed 
significantly elevated binding by anti-(fructosyl group)-antibody. However there 
was little difference in the extent of binding of antibody with the samples 
subjected to uninterrupted and interrupted treatment with fructose. Human IgG 
incubated without the fructose that act as a control showed negligible binding by 
anti-(fructosyl group)-antibody. 
Presence of high concentration of a particular sugar in the reaction 
mixture, slows down the kinetics of AGE formation suggesting the inhibition of 
the conversion of early Amadori rearrangement products to late AGEs by sugar 
and favouring the accumulation of the Amadori intermediates (Khalifah et al, 
1996). In the absence of excess sugar, the reactive groups generated may react 
with other groups of the protein molecule. However on interruption of the reaction 
such a barrier is removed, thus enabling the reaction to rapidly move to the next 
stage (Khalifah et al, 1996; Liggins and Furth, 1997). As the antibodies were 
raised against the BSA treated with fructose under interrupted conditions of 
incubation, the antibodies formed would preferentially bind to AGEs formed 
under such sugar inhibitory conditions and unable to bind to those formed in 
absence of the sugar. Ample evidence is available that show remarkable 
specificity of the anti-AGE-antibodies (Taneda and Monnier, 1994; Koito et al, 
2004). 
4.17. Conclusion and the implications of the study 
Glycation occurs during normal aging and at accelerated rates in diabetes 
and is involved in structural and functional alterations of proteins and other 
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Figure 50: Determination of fructation of human IgG. 
Human IgG incubated with (fH) or without (M) fructose as described in 
legend to Figure 48 was analyzed by Direct Binding ELISA with these 
antibodies. Anti-(fructosyl group)-antibody was used as the first 
antibody at a 1:500 dilution. 
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cellular components (Monnier, 1989). As already known, glucose is a main blood 
sugar and is therefore thought to a major glycating agent in the body.However in 
some tissues such as lens, kidney and peripheral nerve, a polyol-metabolizing 
pathway, converting glucose to sorbitol by aldose reductase and sorbitol to 
fructose by sorbitol dehydrogenase is active and is thought to parcipitate in 
diabetic complications (Gabbay, 1975). 
The resultant fructose is known to be a stronger glycating agent than 
glucose because the population of its acyclic (open chain) form, which is the 
reactive species reacts with protein amino groups at a rate approx. 10-fold than of 
glucose (Bunn and Higgins, 1981). In addition, it has been also shown to be a 
building block of some AGEs (Grandhee and Monnier, 1991). Fructation of 
proteins might therefore play an important role in diabetic complications, 
especially in tissues with high polyol-metabolizing pathway. Although several 
groups are investigating fructose-initiated glycation (Mc Pherson et al, 1988; 
Suarez et al, 1989; Ahmed and Furth, 1992; Pennington and Harding, 1994), an 
adequate method of distinguishing fructated protein is not available. 
A novel antibody that specifically recognizes f-uctose-protein adducts was 
raised against fructated-BSA. The affinity purified anti-(fructosyl group)-antibody 
specifically recognized fructated-proteins but not adducts with other sugars like 
glucose, galactose or ribose (Figure 45 and 46). Also, the level of fructation in 
immunoglobulins from various mammalian sources and an avian source 
undergone in vitro incubation with fructose (Figure 47) was appreciably detected 
and differentiated by the anti-(fructosyl group)-antibody on ELISA. Over the 
years, number of studies carried out, show production of number of anti-AGE-
antibodies that exhibit high specificity towards their antigenic adduct (Curtiss and 
Witztum, 1983; John et al, 1993). Polyclonal antibodies raised against 
pentosidine by Taneda and Monnier (1994) detected by ELISA reacted strongly 
with free pentosidine but not with its structural analogs. Moreover findings of 
Miyazawa et al. (1998) compliments that of ours, as they also raised antibody 
against fructated lysine which specifically recognized proteins incubated with 
fructose but not with other reducing sugars. 
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The specificity of the antibody raised in this study was further elucidated 
by a set of experiments involving interrupted glycation (Figures 48, 49 and 50). 
Human IgG subjected to uninterrupted and interrupted treatment with fructose 
when tested on ELISA by the anti-(fructosyl group)-antibody showed no 
significant increase in immunoreactivity towards the samples subjected to 
interrupted incubation as expected. Thus indicating that the antibody raised 
against the fructcsyl group resulting from continuous incubation were highly 
specific towards epitopes on the fructated adducts formed under similar conditions 
(Vay et ah, 2000; Nagai et al, 2003). 
Since there is no specific, reliable method to detect glycation by fructose, 
even though its involvement in glycation is evident (Dills, 1993), our 
immunological method which specifically recognizes fructation could prove to be 
useful. We further propose that this novel antibody should aid in clarifying the 
roles of the polyol pathway and its relationship to the glycation reactions in 
diabetic complications and would also be beneficial for clinical diagnosis and 
could provide the basis for determination of whether or not an inhibitor of the 
poiyol pathway should be administered. 
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Abstract 
Background: Immunoglobulins undergo non-enzymatic glycation reaction with sugars both in vivo and in vitro. Effects of glycation on the ability 
of the antibodies to bind antigens are contradictory. Antibodies raised in various animals may also be exposed to high concentration of sugars that 
are added during freeze-drying/pasteurization for preservation. 
Methods: IgG isolated from the sera of goat, human, rabbit, mouse, buffalo as well as IgY from hen egg yolk was subjected to in vitro glycation 
with fructose. The behavior of glycated IgG was investigated by SDS-PAGE, hyperchrotnicity at 280 nm, tryptophan fluorescence and new 
fluorescence. 
Results: Marked variations were observed in the response of the immunoglobulins derived from various animals to incubation with fructose. Also, 
incubation of anti-glucoseoxidase (GOD) antibodies with fructose resulted in a rapid loss of their ability to bind the enzyme antigen as revealed by 
immunodiffusion and ELISA. DETAPAC and EDTA were quite protective but were unable to completely prevent the fructose-induced alterations. 
Conclusions: Immunoglobulins derived from goat, human, rabbit, mouse, buffalo and hen egg yolk undergo remarkable structural alterations on 
incubation with fructose. The susceptibility of the immunoglobulins to the modification however differed remarkably. The goat IgG was most 
recalcitrant while hen egg yolk IgY was most susceptible to the alterations. DETAPAC or EDTA restricted the fructose-induced alterations 
remarkably. 
© 2006 Elsevier B.V. All rights reserved. 
Keywords: Fructation; Glycation IgG; IgY 
1. Introduction 
Impaired resistance to infection has long been associated 
with uncontrolled diabetes f 1 31. While the exact mechanism of 
enhanced susceptibility of diabetics to infections is incomplete-
ly understood, potential candidates include immunoglobulins 
that contribute towards humoral immunity. Available evidences 
suggest that glycation of IgG, IgA and IgM is enhanced in the 
blood of diabetics [ 4 - 7 ] . Immunoglobulins are also readily 
Abbreviations: DETAPAC, diethylcnetriaminepenta acetic acid; EDTA, 
clliylcncdianiinctclraacctic acid; ELISA, enzyme linked immunosorbent assay; 
GOD, glucose oxidase; IgG, immunoglobulin G; PAGE, polyacrylamide gel 
electrophoresis; PEG, polyethylene glycol; ROS, reactive oxygen species; SDS, 
sodium dodecyl sulphate; TNBS, 2, 4, 6, trinitrobcnzensulphonic acid. 
* Corresponding author. Department of Biochemistry, Faculty of Life 
Sciences, Aligarh Muslim University, Aligarh 202002, India. Tel.: +91 571 
2700741; fax: +91 571 2721776. 
E-mail address: msalecmuddin(.«;reililTmail.coni (M. Saleemuddin). 
glycated in vitro under conditions that mimic the diabetic 
circulation [8]. In view of the long circulating life and 
predominant role in immune protection, IgG glycation has 
attracted greater attention. In addition, IgGs are rich in lysine 
making them highly potential protein glycation targets. Danze 
et al. [4] observed that preferential glycation of fab fragments 
especially in the Fd region of IgG isolated from the sera of 
diabetic subjects but failed to detect the binding jf light chain 
from the glycated IgG| to boronate supports Subsequent 
studies by Menini et al. [7] also suggested that gl) cation occurs 
mainly in Fab region of IgM. Using MALDI/MS and computer 
modeling, Lapolla et al. [9,10] concluded that about 2 times 
more glycation sites are present in Fab than in the Fc region of 
the IgG. More recently Vrdoljak et al. [S] however failed to 
notice high susceptibility of any specific region of IgG to 
glycation. 
Reports on the effects of glycation on biological function of 
the immunoglobulins are also contradictory. The first proposal 
0009^8981/$ - sec front matter © 2006 Elsevier B.V. All rights reserved. 
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that glycation impairs the functional ability of IgG was based on 
the observation that less complement is fixed by the glycated 
IgG fll) . Morin et al. [12] however failed to observe 
impairment either in the complement fixation or antigen 
binding resulting from the immunoglobulin glycation. Dolho-
fer-Bleisner et al. [13] in a subsequent study reported that 
complement fixation and protein A binding are markedly 
impaired by glycation but did not observe significant effect of 
immunoglobulin glycation on the antigen binding. Studies of 
Sasaki etal. [14], Kaneshige [5] and Kennedy et al. [15] provide 
convincing evidence that glycation of monoclonal antibodies 
impairs their functional ability to bind to their respective 
antigens. We have however shown in a recent study that anti Cu, 
Zn-superoxide dismutase antibodies may protect the enzyme 
antigen against glycation-induced inactivation [16]. 
Majority of studies on immunoglobulin glycation have been 
carried out using glucose as the reactive sugar. Fructose having 
over 300 times as many highly reactive open chain structures 
[17] may therefore facilitate glycation reactions to a larger 
extent than glucose [! N. 19 j. It has also been shown earlier that 
fructose causes more extensive protein crosslinking than 
glucose [1SJ. Tryptophan fluorescence measured as an index 
of advanced glycation products increased linearly for human 
serum albumin with glucose but exponentially with fructose 
[20]. The role of fructose in in vivo AGE formation especially in 
diabetes and some dietary situation is also being increasingly 
realized [21.22], Fructose is therefore used widely as a model 
sugar in studies on glycation. 
Antibodies raised in a variety of animals for analytical and 
other applications and sugars are added to prevent their 
precipitation, facilitate freeze-drying while pasteurization of 
immunoglobulins in the presence of sugars is undertaken to 
inactivate pathogens [8], It was therefore considered of interest 
to investigate if immunoglobulins derived from some mamma-
lian and an avian source differ in their susceptibility to 
glycation. 
2. Materials and methods 
GOD, DEAE-Ccllulosc, DETAPAC, alkalinephosphata.se antirabbit IgG 
conjugate and p-nitrophcnyl phosphate were from Sigma Chemical Co. (St. 
Louis, MO) while EL!SA plates were from Nunc (Rockildc, Denmark) and 
Scphacryl S-200 HR was from Amcrsham Bioscicnccs (Uppsala, Sweden). 
Those used for electrophoresis and immunodiffusion and other chemicals 
including fructose, PEG 6000, EDTA and TNBS were from SRL Chemicals 
(Bombay, India). The remaining chemicals and reagents used in the study were 
of analytical grade. 
2.1. Immunization 
GOD was injected in healthy albino rabbits weighing 2-3 kg for inducing 
the production of antibodies. The animals received subcutancously 0.5 ml of 
0.6 g/1 antigen dissolved in 0.02 mol/1 sodium phosphate buffer pH 7.2, mixed 
and emulsified with equal volume of Frcund's complete adjuvant as first dose. 
Booster doses of 0.3 g/1 antigen were administered weekly for 3 weeks after 
resting the animais for iS days. After each booster dose, blood was collected 
from the car vein and allowed to clot at room temperature for 3 h and serum was 
collected by ccntrifugation at 1600 xg for 20 min at 4 °C. Formation of the 
antibodies was monitored by immunodiffusion in agarose and direct ELISA 
respectively, 
2.2. Isolation and purification of IgG 
IgGs from goat, human, rabbit, mouse and buffalo sera were isolated by a 
slight modification of the method as described by Fahcy and Terry |23i. The 
IgGs were precipitated with ammonium sulfate at 4 °C and the fraction between 
20-40% final saturation was collected by ccntrifugation at 1600 xg for 20 min at 
4 °C. The pellet was redissolved in a minimum volume of 0.02 mol/1 sodium 
phosphate buffer, pH 7.2 and subjected to extensive dialysis against the buffer. 
The dialysed fraction was further purified by ion exchange chromatography on 
DEAE cellulose and homogeneity was determined by native and SDS-PAGE 
[24]. 
2.3. Purification of immunoglobulin Y from hen egg yolk (IgY) 
Hen egg yolk IgY was isolated by the procedure of Poison ct al. \Z^\. 
Briefly, the egg yolks were separated from whites and broken by dropping 
through a funnel into a graduated cylinder. An equal volume of buffer 
(0.01 mol/1 phosphate, 0.1 mol/1 NaCl, pH 7.5 containing 0.1 g/1 NaN,) was 
added and the mixture stirred thoroughly. Pulverized PEG 6000 was added by 
stirring to a concentration of 35 g/1 to facilitate dissolution. The precipitate that 
formed was pelleted by ccntrifugation at 13,000 xg for 10 min and supernatant 
was decanted and filtered through a cheesecloth. PEG was added to bring the 
final concentration of 120 g/1, and the mixture stirred thoroughly and 
centrifuged at 13,000 xg for 10 min. The pellet obtained was redissolved in 
0.01 mol/1 phosphate buffer, pH 7.5 containing 0.1 mol/1 NaCl to the original 
yolk volume and PEG added to a final concentration of 120 g/1. The resulting 
precipitate was separated by ccntrifugation and supernatant was discarded. 
The pellet was subjected to two more washings with the buffer to extrude 
PEG. The IgY pellet was dissolved in 0.05 mol/1 Tris, pH 7.9, containing 
0.001 mol/1 EDTA and 0.2 g/1 NaN, The IgY fraction obtained thus was 
further purified on DEAE-Ccllulose [26]. 
2.4. In vitro glycation of immunoglobulin G with fructose 
The immunoglobulins (1 g/1) in 0.02 mol/1 phosphate buffer, pH 7.2 were 
incubated with fructose at a final concentration of 0.1 mol/1. Where indicated 
0.025 mol/1 DETAPAC and EDTA were included. The mixtures were sterilized 
by filtration through a 0.2 (.im pore-size nitrocellulose filter and then incubated at 
37 °C for 8 days under sterile aerobic conditions. IgG incubated without fructose 
under the same conditions served as control [27]. 
2.5. SDS-PAGE 
SDS-PAGE of the IgG/[gY was carried out in a slab gel electrophoresis 
apparatus manufactured by Biotech India as described earlier [24|. A resolving 
gel of 100 g/1 acrylamidc in tris-HCl buffer, pH 8.8 with I g/1 SDS was used. 
Silver staining of the gels was performed for visualization of protein bands U H 
2.6. Effect of glycation on antigenicity of antibodies 
Immunodiffusion was performed essentially by the method of Ouchtcrlony 
129], Control immunoglobulins and those incubated for various durations with 
fructose in the absence or presence of DETAPAC and EDTA were added to the 
outer wells of agar plates while the central well contained appropriate amount of 
respective antigen. The plates were incubated for 12-24 h in a moist chamber at 
room temperature, 30 °C. 
2.7. Direct ELISA 
Ninety-six welled immunoplatcs were first coated with suitable amount of 
GOD (10 pg/ml) and incubated at room temperature for 2 h. The plates were 
washed 4 times with Tris buffer saline (0.010 mol/1 tris, 0.150 mol/1 NaCl, pH 
7.4) containing 0.5 ml/1 Twccn-20 in order to remove unbound proteins incubated 
for 1 h with 10 g/1 BSA in TBS. The fructose-treated anti-GOD antibodies, 
diluted to 1:100 with TBS, were added and incubation continued overnight at 
4 °C. After four washes, alkaline phosphatase anti rabbit IgG conjugate (1:2000 
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Fig. I. SDS-PAGE of purified IgG from mammalian sources and an avian 
source. Lanes I, 2, 3, 4, 5 and 6 contain goat IgG, human IgG, rabbit IgG, 
buffalo IgG. hen IgYand mouse IgG respectively. Lane 7 contains molecular 
weight markers. The samples were subjected to SDS-PAGE in the presence of 
|^-mcrcaptocihanol. Twelve microliters of I mg/ml immunoglobulin samples 
were loaded in each lane. The gels were silver stained for visualization of 
protein bands. 
dilutions in TBS) was added and the plates were incubated for 2 h at room 
temperature. The plates were washed extensively and phosphatase activity 
detected by addition of 50 ul of p-nitrophenyl phosphate solution containing 
H202. The reaction was terminated by addition of 50 JJI of 1 mol/l H2SOj to each 
well and the absorbancc at 410 nm recorded in an ELISA reader [30], 
2.8. Absorbancc and fluorescence measurements 
The UV absorption measurements of control immunoglobulins and those 
incubated with fructose were obtained by measuring the absorption between 
200-400 nm in a Shimadzu spectrophotometer using a cuvette of 1.0 cm path 
length. Three hundred micrograms of samples in a total volume of 1.0 ml was 
taken for the analysis. Similarly, control and fructose incubated immunoglobu-
lins (0.1 g/l) were studied by measuring intrinsic fluorescence at 25 ±0.2 °C in a 
Hitachi F2000 spcctrofluoromctcr (Tokyo, Japan). The samples were excited at 
285 nm and emission range was taken at 310-460 nm. Fluorescence 
measurements were also made at 370 nm excitation and an emission range of 
400-500 nm. 
2.9. Amino group estimation 
The exposed amino groups of immunoglobulins were determined as described 
by Habccb [311. To the immunoglobulin sample in a total volume of 1.0 ml of 
0.1 mol/l sodium tetraborate buffer, pH 9.3 was added 25 pi of 0.3 mol/l TNBS. 
The tubes were agitated instantly to ensure complete mixing and allowed to stand 
for 30 min at room temperature, 30 °C and absorbancc recorded at 420 nm. 
3. Results and discussion 
3.1. SDS-PAGE of the immunoglobulins incubated with fructose 
the bands apparently results from such effects. The fructose-
induced loss of band intensity appeared most prominent in case 
of IgY followed by buffalo, mouse, rabbit, human and goat IgG. 
While appearance of small peptides could not be noticed, the 
presence of the material that failed to enter into the gels and 
could be silver stained could be detected in some gels, 
particularly in the IgY and rabbit IgG. Intermolecular cross-
linking of the immunoglobulins may result in the formation of 
aggregates, which may be too large to enter the gel pores and 
hence may not be detected on the gels. Alternatively, 
fragmentation of the immunoglobulins to very small peptides 
may however go undetected in the gels. Our unpublished data 
on gel filtration however suggests that less than 10% of protein 
can be detected as large molecular weight fraction after 
incubation of IgG with fructose and appears as the fraction 
that is excluded from Sephacryl S-200. This suggests the 
formation of aggregates may not be the principal cause of the 
observed decrease intensity of the immunoglobulin band. 
In all the immunoglobulin samples investigated, the intensity 
of the large polypeptide decreased more rapidly as compared to 
that of the small molecular weight counterpart. In fact 
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The IgG was purified from the sera of goat, human, rabbit, 
buffalo, and mouse, the IgY was purified from hen egg yolk. 
The immunoglobulins were analyzed by SDS-PAGE in the 
presence of the thiol reductant p-mercaptoethanol. All the 
immunoglobulins migrated characteristically as one large 
molecular weight (50 kDa) and a small molecular weight 
(25 kDa) band suggesting homogeneity (Fig. I). Incubation of 
the immunoglobulins with fructose resulted in a time-dependent 
decrease in the intensity of the bands (Fig. 2). Glycation of 
proteins has been shown to result in protein degradation and/or 
crosslinking [32] and the observed decrease in the intensity of 
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( 1 . 1 
1 2 3 4 5 6 
(F) 
Fig. 2. Effect of incubation on IgG derived from sera of various animals 
incubated with fructose. The IgG isolated from goat (A), human (B), rabbit 
(C), mouse (D), buffalo (E) and hen egg yolk IgY (F) was incubated with 
0.1 mol/l fructose as detailed in the text. Lane I contains immunoglobulin 
incubated without fructose for 8 days. Lanes 2-6 contain sample incubated 
with fructose for 1, 3, 5, 6 and 8 days respectively. The samples were subjected 
to SDS-PAGE in the presence of ^-mcrcaptocthanol. Twelve microlitrcs of 
1 mg/ml immunoglobulin samples were loaded in each lane. The gels were 
silver stained for visualization of protein bands. 
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Fig. 3. SDS-PAGE of Goat IgG (A) and Buffalo IgG (B) incubated with fructose 
in the absence or presence of metal chelators (DETAPAC and EDTA). Lane 1 
contains immunoglobulin incubated without fructose. Lane 2 contains sample 
incubated with 0.1 mol/1 fructose. Lanes 3 and 4 contain sample incubated with 
fructose in the presence of 0.025 mol/1 DETAPAC or EDTA respectively. All the 
samples were incubated for 8 days. 
incubation for 8 days with fructose resulted in near complete 
disappearance of the large molecular weight band in case of the 
IgY mouse and rabbit IgG, while significant staining in the 
region of low molecular weight band was still evident (Fig. 2). 
Selective loss of the large molecular weight band also suggests 
proteolysis rather than intermolecular aggregation in the 
fructose-treated immunoglobulins. 
In order to detect the possible role of metal ions in the 
fructose-induced alterations in the immunoglobulins, effect of 
inclusion of the chelating agents DETAPAC and EDTA was 
investigated. Fig. 3 shows that even after 8 days of incubation, 
the IgG derived from goat and buffalo immunoglobulin samples 
incubated with fructose, especially in the presence of DETA-
PAC, contained bands of comparable intensity with controls. 
The chelating agents were also protective in case of the 
immunoglobulins derived from other animals (data not 
included). Earlier studies have shown that DETAPAC and 
EDTA restrict glucose-induced fragmentation of protein and 
autoxidation in the presence as well as in the absence of added 
metal ions, suggesting the role of trace metal ions present in the 
buffers in the autoxidation of sugars and transformation of 
Maillard products to AGE [33.34]. Apparently the trace metal 
ions also play an important role in the induction of alterations 
observed in case of immunoglobulins incubated with fructose in 
this study. 
3.2. Effect of incubation with fructose on the binding of anti-
GOD IgG to GOD 
The IgG isolated from the serum of rabbits immunized with 
GOD also facilitated investigations on the effect of glycation on 
the ability of the antibodies to bind to the enzyme-antigen. The 
• 
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Fig. 4. Ouchterlony double immunodiffusion of fructose-treated rabbit IgG against its antigen. Immunodiffusion was performed in 1% agarose gel prepared in normal 
saline. The central wells contained 40 ul of 1 mg/ml antigen (GOD) while same amount of the control sample (A) and anti-GOD IgG incubated with 0.1 mol/1 fructose 
in the absence (B and C) or presence of 0.02S mol/1 DETAPAC (D and E) or EDTA (F and G) for 1 and 3 days were added to the outer wells of different plates. 
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Fig. 5. Effect of incubation with fructose on ELISA analysis of anti-GOD 
antibodies. ELISA analysis of anti-GOD IgG incubated with buffer (c) or fructose 
in the absence (H) or presence of (0.025 mol/1) DETAPAC (ffl"l) or EDTA ((TTl) 
was performed as described in Methods. All the values arc mcaniS.D. for three 
experiments performed in duplicate. 
anti-GOD antibodies showed a remarkable decrease in the 
ability to bind to GOD on incubation with fructose as revealed 
by immunodiffusion (Fig, 4) and ELISA (Fig. 5). At the end of 
8 days of incubation there was a near complete loss of antigen 
binding as evident from lack of precipitin lines on immunodif-
fusion and absence of significant binding to GOD as revealed 
by the ELISA. Anti-GOD-IgG incubated with fructose in the 
presence of metal chelators (DETAPAC and EDTA) showed 
appreciable precipitin lines on immunodiffusion and significant 
binding to GOD as revealed by ELISA. These findings 
substantiate the protective effect of the chelating agents 
observed against alterations in electrophoretic behavior, and 
the role of trace metal ions in protein glycation and autoxidation 
\XM\. 
3.3. Effect of incubation with fructose on UV absorption and 
fluorescence 
The fructose-induced alterations on the immunoglobulins 
were further examined with respect to their chromophoric and 
fluorophoric properties. The UV spectra of all the IgG samples 
incubated with fructose showed marked increase in absorbance 
at 280 nm, as compared to the respective native controls. 
However, the magnitude of hyperchromicity varied remarkably 
among the immunoglobulins derived from various animals. 
Maximum hyperchromicity was observed in case of human IgG 
followed by mouse IgG, buffalo IgG, rabbit IgG, hen IgY and 
goat IgG (Fig. 6a). Hyperchromicity in the UV region can be 
attributed to the exposure of the chromophoric aromatic 
residues due to unfolding of the molecules and/or fragmentation 
of the immunoglobulins [35). The large variations observed in 
the hyperchromicity among various immunoglobulins are also 
suggestive of major differences in conformational alterations 
and/or fragmentation of the immunoglobulins resulting from the 
fructose-mediated glycation reactions. EDTA and DETAPAC, 
which were highly effective in restricting sugar-induced 
alterations evident in SDS-PAGE, also markedly decrease the 
fructose-induced hyperchromicity in the immunoglobulins (data 
not included). Maximum hyperchromicity was observed in case 
of human IgG followed by mouse IgG, buffalo IgG, rabbit IgG, 
IgY from hen egg yolk and goat IgG. The order of fructose-
induced hyperchromicity among the immunoglobulins was 
different from that of alterations revealed by SDS-PAGE. Goat 
IgG was most resistant and exhibited minimum alterations both 
in hyperchromicity and electrophoretic behavior. 
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Fig. 6. Hyperchromicity, tryptophan fluorescence and new fluorescence of 
immunoglobulin incubated with fructose. Immunoglobulins were dialyscd 
and equivalent quantities of protein were taken for ultraviolet spectroscopy 
(a), tryptophan fluorescence (b) and new fluorcsecncc(c). The immunoglob-
ulin samples were incubated with 0.1 mol/1 fructose for 8 days. Relative 
tryptophan fluorcsccncc% and new fIuorcsccnec% were calculated taking the 
value of sample incubated without fructose as 100. All values arc mcan + S.D 
for three experiments performed in duplicate. 
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The exposed amino groups of immunoglobulins derived from various animals 
Immunoglobulin source Amino group number (per molecule)'' 
Goat scrum I7±2 
Mouse scrum 20±3 
Human scrum 22 ±3 
Rabbit scrum 25 ±3 
Buffalo serum 27 ±2 
Hen egg yolk 30±2 
'' All the values arc mcan±S.D. for 3 experiments performed in duplicate. 
Quenching of tryptophan fluorescence (285 nm exc./335 nm 
em.) of the immunoglobulins was also measured as an 
additional index of alteration in the structure/conformation. 
Incubation with fructose resulted in quenching of tryptophan 
fluorescence in all the immunoglobulins (Fig. 6b), but the 
magnitude of quenching also varied very markedly among them 
with maximum quenching observed in case of fructose-treated 
buffalo lgG; hen egg yolk IgY revealed minimum quenching. 
Fluorescence spectra showed a red shift of emission peak by 
5 nm, in case of hen IgY incubated with fructose while the shift 
was of 10 nm with mouse IgG treated with the sugar. Loss of 
tryptophan fluorescence is ascribed to the destruction of 
tryptophan and/or modification of the tryptophan microenvi-
ronment [36,37]. 
Increase in the new fluorescence (370 nm exc./440 nm em.) 
has been shown earlier to be a characteristic of the several 
glycated proteins and used as a measure of protein glycation 
[38j. The new fluorescence is ascribed to the formation of 
various new fluorophores, whose relative contribution may vary 
broadly depending on the site, extent of glycation and 
accompanying autoxidation [39]. A marked increase in the 
new fluorescence was also observed with all the IgG and IgY 
incubated with fructose (Fig. 6c). The variation in the 
enhancement of new fluorescence among the immunoglobulins 
was however less marked as compared to those observed with 
other parameters. 
3.4. Exposed amino groups of the immunoglobulins 
Table I shows the amino groups of various native 
immunoglobulins accessible for reaction with TNBS. Goat 
IgG contained the minimum number of exposed amino groups 
per molecule while they were maximum in the hen IgY. This 
suggests a reasonable correlation between the number of 
exposed amino groups and fructose-induced alterations in the 
electrpphoretic mobility and new fluorescence. Such correlation 
between the amino groups and alteration in hyperchromicity as 
well as tryptophan fluorescence was however not observed. 
Thus, goat IgG with minimum number of exposed aminogroups 
was most recalcitrant among the immunoglobulins investigated 
as evident from SDS-PAGE, hyperchromicity in the UV and 
development of new fluorescence and hen IgY were found to be 
most susceptible. This is not unexpected since glycation of 
proteins begins with the reaction of sugars mainly, the amino 
groups and supports the earlier observation of Lapolla et al. 
[9.10] that exposed amino groups may play an important role in 
determining the susceptibility to glycation by sugars. The 
glyoxidation products of sugars like a-ketoacids on the other 
hand, react preferentially with the guanidine group of arginine 
[40]. The number of reactive amino groups of a protein alone 
may not therefore determine the magnitude of alterations that 
accompany glycation. Among the side chain amino groups of 
protein those with low pKa and more importantly those that 
could afford low acid-base catalysis are the ones that are 
preferentially modified during glycation [41]. This may explain 
the observation that mouse IgG with fewer amino groups as 
compared to human and rabbit IgG appears more susceptible to 
fructose-induced alterations. 
Since IgG derived from various animals exhibits remarkable 
structural similarity, minor differences in structure may 
contribute significantly towards the alterations resulting from 
glycation by sugars. It is likely that specific location of the 
susceptible amino acid side chains in or close to the antigen 
binding sites may determine the sensitivity to glycation-induced 
loss in ability to bind to antigen. Sasaki et al. [14] and Kennedy 
et al. f 15] reported glycation induced loss of ability of mouse 
monoclonal antibodies to bind to the antigen. Our studies 
carried out using the anti-GOD antibodies raised in rabbits 
support their observations. As evident from Figs. 2 and 6 
remarkable similarities exist in the response of mouse and rabbit 
immunoglobulins to the alterations induced by fructose 
indicating their structural similarity. It is however not unlikely 
that different antibodies raised in the same animal may differ in 
their sensitivity to glycation depending upon the reactivity of 
amino acids in and around the antigen/epitope binding sites. 
To conclude, this study suggests that fructose-induced 
alterations in immunoglobulins derived from various animals 
leading to fragmentation/crosslinking, hyperchromicity, trypto-
phan fluorescence quenching and development of new 
fluorescence vary markedly. Goat IgG appeared most recalci-
trant and hen egg yolk IgY most susceptible by majority but not 
all parameters. These studies substantiate the work of Sell et al. 
[42], who also observed marked variation in collagen AGEs 
among different species of animals. Metal ion chelators like 
EDTA and DETAPAC appear remarkable in the ability to 
restrict the alterations and inclusions of these may be useful 
during antibodies storage in the presence of sugars. 
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